```
 37.5% PROCESSED     2000 ITERATIONS                                 5 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.03

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       102399 TO   111161
PROJECTED ANSWERS:              47 TO      485

L4             5 SEA SSS SAM L3

=> s l3 full
FULL SEARCH INITIATED 06:21:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   107216 TO ITERATE

100.0% PROCESSED   107216 ITERATIONS                             220 ANSWERS
SEARCH TIME: 00.00.01

L5           220 SEA SSS FUL L3

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               177.50     177.71

FILE 'CAPLUS' ENTERED AT 06:21:57 ON 30 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 30 Jul 2007  VOL 147 ISS 6
FILE LAST UPDATED: 29 Jul 2007  (20070729/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l5
L6           27 L5

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                0.47     178.18

FILE 'CAPLUS' ENTERED AT 06:22:23 ON 30 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
```

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 30 Jul 2007 VOL 147 ISS 6
FILE LAST UPDATED: 29 Jul 2007 (20070729/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d 16 ibib abs tot

---Logging off of STN---

END

Unable to generate the STN prompt.
Exiting the script...

END

Unable to generate the STN prompt.
Exiting the script...

---Logging off of STN---

END

Unable to generate the STN prompt.
Exiting the script...

END

Unable to generate the STN prompt.
Exiting the script...

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptaylc1626

PASSWORD:
THIS LOGINID IS CURRENTLY IN USE.
DO YOU WISH TO RESUME THE PREVIOUS SESSION? Y/(N)/?:Y

THE PREVIOUS SESSION IS BEING DISCONNECTED.
PLEASE LOG IN AGAIN TO BE RECONNECTED.
SYSTEM LOGOFF AT 06:30:19 ON 30 JUL 2007 US EASTERN TIME

Connection closed by remote host

A new logon attempt will be made when this window closes. If you chose to RESUME PREVIOUS SESSION, then continue with the logon process as normal. If not, choose Cancel or <ESC> to interrupt the logon process.

FILE COVERS 1907 - 30 Jul 2007 VOL 147 ISS 6
FILE LAST UPDATED: 29 Jul 2007 (20070729/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d ibib abs tot

L6 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1026833 CAPLUS Full-text
DOCUMENT NUMBER: 143:326090
TITLE: Preparation of arylmethoxyphenyl-alkylcarboxylic acids and related derivatives for use in treating metabolic disorders
INVENTOR(S): Akerman, Michelle; Houze, Jonathan; Lin, Daniel C. H.; Liu, Jiwen; Luo, Jian; Medina, Julio C.; Qiu, Wei; Reagan, Jeffrey D.; Sharma, Rajiv; Shuttleworth, Stephen J.; Sun, Ying; Zhang, Jian; Zhu, Liusheng
PATENT ASSIGNEE(S): Amgen Inc., USA; et al.
SOURCE: PCT Int. Appl., 163 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005086661	A2	20050922	WO 2005-US5815		20050224
WO 2005086661	A3	20060504			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2005220728	A2	20050922	AU 2005-220728		20050224
AU 2005220728	A1	20050922			
CA 2558585	A1	20050922	CA 2005-2558585		20050224
EP 1737809	A2	20070103	EP 2005-723623		20050224
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU					
CN 1946666	A	20070411	CN 2005-80012709		20050224
US 2006004012	A1	20060105	US 2005-67377		20050225
MX 2006PA09793	A	20061030	MX 2006-PA9793		20060828
US 2007142384	A1	20070621	US 2006-591214		20060828
NO 2006004362	A	20061122	NO 2006-4362		20060926
PRIORITY APPLN. INFO.:			US 2004-548741P	P	20040227
			US 2004-601579P	P	20040812
			WO 2005-US5815	W	20050224

OTHER SOURCE(S): MARPAT 143:326090

GI



II

AB Title compds. Q-L1-P-L2-M-X-L3-A [Q = H, (hetero)aryl, alkyl, etc.; L1 = bond, alkylene, heteroalkylene, O, etc.; P = (hetero)arom., cycloalkylene, etc.; L2 = bond, alkylene, heteroalkylene, etc.; M = (hetero)arom., cycloalkylene, arylalkylene, etc.; X = divalent alkyl, (un)substituted-N; O, SO0-2; L3 = bond, alkylene, heteroalkylene, etc.; A = COOH, tetrazolyl, SO3H, PO3H2, etc.; I] are prepd. For instance, (S)-3-[4-((4'- trifluoromethyl-1,1'-biphenyl-3-yl)methoxy)phenyl]hexan-4-ynoic acid (II) is prepd. in 5 steps from (S)-3-(4-hydroxyphenyl)hexan-4-ynoic acid Me ester (prepn. given), 4-(trifluoromethyl)phenylboronic acid and 3-bromobenzoic acid. II has an EC50 < 0.1 .mu.M for human G protein-coupled receptor GPR40. I are useful for the treatment of type II diabetes.

L6 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:531809 CAPLUS Full-text
DOCUMENT NUMBER: 144:192162
TITLE: Synthesis, characterization of some 1-(2-hydroxy-phenyl)-3-(1-phenyl-3-thiophen-2-yl-1H-pyrazol-4-yl)-propenone, 3-chloro-2-(1-phenyl-3-thiophen-2-yl-1H-pyrazol-4-yl)-chromon-4-one, and 2-(1'-phenyl-3'-thiophen-2-yl-3,4-dihydro-2H,1H'-[3,4]bipyrazol-5-yl)-phenol
AUTHOR(S): Halnor, V. B.; Joshi, N. S.; Karale, B. K.; Gill, C. H.
CORPORATE SOURCE: P.G. Dept. of Chemistry, S.S.G.M. College, Kopargaon, 423 601, India
SOURCE: Heterocyclic Communications (2005), 11(2), 167-172
CODEN: HCOMEX; ISSN: 0793-0283
PUBLISHER: Freund Publishing House Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:192162
AB Base catalyzed condensation of 2-hydroxyacetophenones with thiophenylpyrazolylaldehyde gives compds., 1-(3,4,5-substituted-2-hydroxy-phenyl)-3-(1-phenyl-3-thiophen-2-yl-1H-pyrazol-4-yl)-propenones. The propenone compds. on oxidative cyclization with DMSO-CuCl2 gives 3-chloro-2-(1-phenyl-3-thiophen-2-yl-1H-pyrazol-4-yl)-chromon-4-ones. The propenone compds. on condensation with hydrazine hydrate gives 2-(1'-phenyl-3'-thiophen-2-yl-3,4-dihydro-2H,1H'-[3,4]bipyrazol-5-yl)- phenol 5. The products 3, 4 and 5 were characterized by IR, 1H NMR and mass spectroscopy.
REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:395278 CAPLUS Full-text
DOCUMENT NUMBER: 142:447209
TITLE: Preparation of .alpha.-hydroxyimino-.beta.-benzylpropanoate derivatives as PPAR.gamma. and PPAR.alpha. agonists for the treatment of diabetes mellitus and inflammation diseases
INVENTOR(S): Kim, Geun Tae; Koh, Jong Sung; Han, Hee Oon; Kim, Seung Hae; Kim, Kyoung-Hee; Chung, Hee-Kyung; Kim, Yeon Chul; Kim, Misun; Koo, Ki Dong; Yim, Hyeon Joo; Hur, Gwong-Cheung; Lee, Sun Hwa; Lee, Chang-Seok; Woo, Sung Ho
PATENT ASSIGNEE(S): LG Life Sciences Ltd., S. Korea
SOURCE: PCT Int. Appl., 211 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005040127	A1	20050506	WO 2004-KR2729	20041027
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
KR 2005040746	A	20050503	KR 2004-86055	20041027
PRIORITY APPLN. INFO.:			KR 2003-75037 A	20031027
			KR 2003-75041 A	20031027
			KR 2003-75046 A	20031027

OTHER SOURCE(S): MARPAT 142:447209
GI



I



II

AB Title compds. I [wherein A = (un)substituted (cyclo)alkyl, (hetero)aryl, amine, amido, alkoxy, sulfonyl or sulfanyl; B, D, X = H or alkyl; E = H, alkyl or aryl; and pharmaceutically acceptable nontoxic salts, physiol. hydrolyzable esters, hydrates, solvates, isomers or prodrugs thereof] were prepd. as agonists of peroxisome proliferator-activated receptor gamma (PPAR.gamma.) and alpha (PPAR.alpha.). For example, II was synthesized via etherification of the corresponding phenol (prepn. given) with methanesulfonate ester of the pyrazolemethanol (prepn. given) in 40% yield. I were found to be very effective for accelerating the activity of PPAR.gamma. and PPARa with EC50 values of <1 .mu.M and <1000 nM (<100 nM for II), resp. Therefore, I are useful for treating or preventing PPAR.gamma.- and PPARa-related diseases, such as diabetes mellitus, its complications and inflammation.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:995925 CAPLUS Full-text
DOCUMENT NUMBER: 141:424182
TITLE: Preparation of pyrazole-amine compounds useful as kinase inhibitors
INVENTOR(S): Dyckman, Alaric; Das, Jagabandhu; Leftheris, Katerina; Liu, Chunjian; Moquin, Robert V.; Wrobleski, Stephen T.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004098528	A2	20041118	WO 2004-US13786	20040503
WO 2004098528	A3	20050714		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004248853	A1	20041209	US 2004-838006	20040503
US 7151113	B2	20061219		
US 2005004176	A1	20050106	US 2004-837778	20040503
US 2005159424	A1	20050721	US 2004-838129	20040503
EP 1620108	A2	20060201	EP 2004-760705	20040503
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
US 2006247247	A1	20061102	US 2006-477010	20060628
PRIORITY APPLN. INFO.:			US 2003-467029P	P 20030501
			US 2004-838006	A3 20040503
			WO 2004-US13786	W 20040503

OTHER SOURCE(S): MARPAT 141:424182

GI



I



II

AB The title compds. I [G = Ph, pyridyl; W = CH2O, CO2, NHCHR8, CHR8NH, NHCO(CHR8)r (wherein R8 = H, alkyl; r = 0-2); R1 = H, (un)substituted alkyl, aryl, etc.; R2 = H, (un)substituted alkyl, alkoxy, etc.; R3 = H, CF3, OCF3, etc.; R4 = H, (un)substituted alkyl, halo, etc.; R5 = CF3, OCF3, CN, etc.; X = CONH, NHCO, NHCO2, SO2NH, CO2, or is absent; R6 = H, (un)substituted alkyl, alkoxy, etc.; m = 0-3], useful for treating p38 kinase-assocd. conditions (such as inflammatory disorder) in a mammal (no data), were prepd. E.g., a 3-step synthesis of II, starting from 1-phenyl-5-propyl-1H-pyrazole-4-carbonyl chloride, was given.

L6 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:963181 CAPLUS Full-text
DOCUMENT NUMBER: 141:379941
TITLE: Preparation of quinazoline-2,4-diamines as melanin concentrating hormone (MCH) receptor antagonists
INVENTOR(S): Sekiguchi, Yoshikatsu; Kanuma, Yukihiro; Omodera, Katsunori; Tran, Thuy-ahn; Kramer, Bryan Aubrey; Beeley, Nigel Robert Arnold
PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 988 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
JP 2004315511	A	20041111	JP 2004-95046		20040329
PRIORITY APPLN. INFO.:			JP 2003-93418	A	20030331

OTHER SOURCE(S): MARPAT 141:379941
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. Q-L-Y-R1 [Q = Q1, H2NC(:NH); wherein R2 = NHNH2, NHNHBoc, (un)substituted NH2, morpholino, 4-acetyl-piperazinyl, 4-phenylpiperazinyl; R1 = each (un)substituted C1-16 alkyl, C2-8 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, C3-6 cycloalkenyl, carbocyclyl, carbocyclic alkyl, or heterocyclyl; L = each Q2-Q6 or its cis- or trans-isomer, Q7-Q16; R4 = H, C1-3

alkyl; R5 = H, each (un)substituted carbocyclic aryl or C1-3 alkyl; Y = SO2, CO, a single bond, CH2] or salts thereof are prepd. These compds. are MCH receptor antagonists and used for regulating orphan G protein-coupled receptor SLC-1 and for the prevention and/or treatment of obesity, obesity-related diseases, anxiety, or depression. Thus, hydrogenolysis of benzyl cis-[[4-(4-dimethylaminoquinazolin-2- ylamino)cyclohexyl]methyl]carbamate over 5% Pd-C in MeOH at 50.degree. under H atm. for 3 days gave a soln. of cis-[[4-(4-dimethylaminoquinazolin- 2-ylamino)cyclohexyl]methyl]amine in MeOH which underwent reductive alkylation with 4-bromo-2-trifluoromethoxybenzaldehyde and NaBH(OAc)3 in AcOH/CH2Cl2 to give, after purifn. using HPLC and treatment with 4 N HCl/EtOAc, compd. (I).2HCl. In a high throughput function screen for identifying lead compds., I.2HCl inhibited the human MCH-induced cellular Ca2+ flux with IC50 of 6 .mu.g/mL.

Current app.

L6 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:606448 CAPLUS Full-text
DOCUMENT NUMBER: 141:157111
TITLE: Preparation of pyrazoles and analogs as PPAR modulators for treatment of metabolic disorders, diabetes mellitus, atherosclerosis, and cardiovascular disorders
INVENTOR(S): Conner, Scott Eugene; Ma, Tianwei; Mantlo, Nathan Bryan; Mayhugh, Daniel Ray; Schkeryantz, Jeffrey Michael; Warshawsky, Alan M.; Zhu, Guoxin
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 214 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004063166	A1	20040729	WO 2003-US39119	20031231
WO 2004063166	A8	20050303		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003296404	A1	20040810	AU 2003-296404	20031231
EP 1585733	A1	20051019	EP 2003-815195	20031231
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, BG, CZ, EE, HU, SK				
US 2006241157	A1	20061026	US 2005-540341	20050621
PRIORITY APPLN. INFO.:			US 2003-438563P P	20030106
			WO 2003-US39119 W	20031231

OTHER SOURCE(S): MARPAT 141:157111
GI



I



II

AB Title pyrazoles, imidazoles, and (is)oxazoles I [wherein R1 = H, (un)substituted alkyl, alkenyl, (hetero)aryl(alkyl), arylheteroalkyl, cycloalkylaryl(alkyl); R2 = absent, (hetero)alkyl; R8 = H, alkyl, alkylenyl, halo; R9 = H, (un)substituted alkyl, alkylenyl, halo, aryl(alkyl), heteroaryl, allyl, alkoxy, alkylthio, etc.; R10, R11 = independently H, OH, CN, NO2, halo, oxo, (un)substituted (halo)alkyl, alkoxy, cycloalkyl, (hetero)aryl(alkyl), cycloalkylaryl(alkyl), aryloxy, acyl, carboxy, amino, sulfamoyl, etc.; R32 = bond, H, halo, (halo)alkyl, alkyloxo; E = (un)substituted carboxy(methyl), tetrazolyl(methyl), nitriloalkyl, carboxamido(methyl), sulfonamido(methyl); U = (un)substituted aliph. linker wherein one C of the linker is optionally replaced with O, NH, or S; X = bond, O, S, SO2, NH; Y = bond, CH2, NH; Z1, Z2 = independently N, O, C, whit the proviso that at least one of Z1 and Z2 = N; Z3 = N, O, C; or stereoisomers, pharmaceutically acceptable salts, solvates, and hydrates thereof] were prepd. as peroxisome proliferator activated receptor (PPAR) modulators (no data). For example, chlorination of [3-methyl-1-(4-trifluoromethylphenyl)-1H-pyrazol-4-yl]methanol with MeSO2Cl and TEA in CH2Cl2, followed by coupling with (4-hydroxy-2- methylphenoxy)acetic acid Me ester using Cs2CO3 in acetonitrile and sapon. with NaOH in MeOH provided II. I and their pharmaceutical compns. are expected to be effective in treating and preventing metabolic disorders, diabetes mellitus, atherosclerosis, and cardiovascular disorders (no data).

L6 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:430797 CAPLUS Full-text
DOCUMENT NUMBER: 141:7108
TITLE: Preparation of pyrazoles as modulators of peroxisome proliferator activated receptors (PPARs), in particular PPAR.gamma. agonists
INVENTOR(S): Huck, Jacques; Saladin, Regis; Sierra, Michael
PATENT ASSIGNEE(S): Carex SA, Fr.
SOURCE: PCT Int. Appl., 156 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043951	A1	20040527	WO 2003-EP311855	20031024

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003282051	A1	20040603	AU 2003-282051	20031024
PRIORITY APPLN. INFO.:			EP 2002-360298	A 20021024
			EP 2002-360372	A 20021220
			EP 2002-360373	A 20021220
			US 2003-456954P	P 20030325
			EP 2003-360070	A 20030611
			EP 2003-360091	A 20030724
			WO 2003-EP11855	W 20031024

OTHER SOURCE(S): MARPAT 141:7108
GI



I



II

AB Title compds. I [wherein R1 = H, CF3, (un)substituted alkyl, cycloalkyl, heterocyclyl, etc.; R2 = (un)substituted alkyl, amino, COH, etc.; n = 0-6; R11 and R12 = independently H, alkyl, CO2H and derivs., OH and derivs., NH2 and derivs., etc.; their analogs, derivs., solvates or salts] were prepd. for modulating peroxisome proliferator activated receptors (PPARs), in particular as PPAR.gamma. agonists, and for treating and/or preventing various diseases and conditions mediated by said nuclear receptors, including metabolic or cell proliferative disorders (no data). For example, 1-phenyl-3-(thiophen-2-yl)-1H-pyrazole-4-carboxaldehyde (prepn. given) was reacted with 1-(4-methoxyphenyl)ethanone in isopropanol to give II in 67% yield. II inhibited adipocyte differentiation induced by rosiglitazone by about 68%, demonstrating its antagonistic activity towards human PPAR.gamma.. II induced adipocyte differentiation (25% of rosiglitazone efficacy), proving its human PPAR.gamma. partial agonistic activity. I are useful for treating diabetes, atherosclerosis, hyperglycemia, dyslipidemia, obesity, syndrome X, insulin resistance, hypertension, neuropathy, microvascular diseases (e.g.

retinopathy, nephropathy), macrovascular diseases (e.g. myocardial infarction, stroke, heart failure) in mammals.(no data).

L6 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:951003 CAPLUS Full-text
DOCUMENT NUMBER: 140:16723
TITLE: Preparation of 1,2-azole derivatives with hypoglycemic and hypolipidemic activity
INVENTOR(S): Maekawa, Tsuyoshi; Hara, Ryoma; Odaka, Hiroyuki; Kimura, Hiroyuki; Mizufune, Hideya; Fukatsu, Kohji
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan; Takeda Pharmaceutical Company Limited
SOURCE: PCT Int. Appl., 564 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003099793	A1	20031204	WO 2003-JP6389	20030522
WO 2003099793	A8	20041229		
WO 2003099793	A9	20050210		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2487315	A1	20031204	CA 2003-2487315	20030522
AU 2003241173	A1	20031212	AU 2003-241173	20030522
JP 2004277397	A	20041007	JP 2003-144984	20030522
EP 1513817	A1	20050316	EP 2003-730575	20030522
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006148858	A1	20060706	US 2005-517214	20050301

PRIORITY APPLN. INFO.:			
JP 2002-151405	A	20020524
JP 2002-287161	A	20020930
JP 2003-16748	A	20030124
WO 2003-JP6389	W	20030522

OTHER SOURCE(S): MARPAT 140:16723
GI

(EtOH-acetone), 51; .alpha.-naphthyl, 165-6.degree. (EtOH-acetone), 51.7; 5,6,7,8-tetrahydro-.beta.-naphthyl, 165-6.degree. (EtOH-acetone), 31.7; 5-(2,3-dihydro)indenyl, 178.degree. (EtOH-acetone), 55.4; 3-methyl-4-chlorophenyl, 185-7.degree. (EtOH), 74.3; 2-chloro-5-methylphenyl, 161-3.degree. (EtOH), 47.5; 3-bromo-4-methylphenyl, 186-7.degree. (EtOH), 88; and 3-trifluoromethylphenyl, 136-7.degree. [EtOH-iso-Pr2O], 55.7. Some show slight antiinflammatory activity.

L6 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1968:496713 CAPLUS Full-text
DOCUMENT NUMBER: 69:96713
TITLE: 4-Substituted 1,2-diphenyl-3,5-dioxopyrazolidines
PATENT ASSIGNEE(S): SPOFA, United Pharmaceutical Works
SOURCE: Brit., 6 pp.
CODEN: BRXXAA
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1117679		19680619	GB 1966-51960	19661121
CZ 145219			CZ	
DE 1620440			DE	
FR 1513442			FR	
US 3519640		19700707	US	19661221
PRIORITY APPLN. INFO.:			CS	19651223

GI For diagram(s), see printed CA Issue.
AB Pyrazolidines and their salts with antiinflammatory, analgesic, fibrinolytic, antirheumatic and uricosurgical properties were prepd. To 12.5 g. Na in 750 ml. MeOH is added 126 g. 1,2-diphenyl-3,5- dioxopyrazolidine, the whole added to a soln. of 78.5 g. 1-dimethylamino-4,4-dimethyl-3-pentanone in 200 ml. MeOH, the mixt. refluxed and stirred as a soln. of 62.8 g. Me2SO4 in 150 ml. MeOH is added dropwise over 40-50 min., and the mixt. refluxed and stirred 3 hrs. and worked up to yield 70 g. 1,2-diphenyl-3,5-dioxo-4-(4,4-dimethyl-3 -oxopentyl)pyrazolidine, m. 139-40.degree. (dil. HOAc). Also prepd. were the following I (R and m.p. given): 2-FC6H4, 175-7.degree. (EtOH); 3-FC6H4, 149-50.degree.; 4-FC6H4, 106-7.degree.; 2-IC6H4, 135-7.degree.; 3-IC6H4, 114-15.degree.; 4-IC6H4, 151-2.degree.; 2-ClC6H4, 125-7.degree.; 3-ClC6H4, 119-20.degree.; 2-BrC6H4, 138-9.degree.; 3-BrC6H4, 119-21.degree.; 3-F3CC6H4, 128-30.degree. (EtOH); 2,5-ClMeC6H3, 118-20.degree. (EtOH); 3,4-BrMeC6H3, 146-8.degree.; 4-MeSC6H4, 126-7.degree.; 2,5-Me2C6H3, 129-30.degree.; 3,4-Me2C6H3, 147-8.degree.; 2,4,6-Me3C6H2, 123-5.degree.; 4-EtC6H4, 130-2.degree.; 4-iso-PrC6H4, 122-3.degree.; 4-BuC6H4, 122-4.degree.; 4-iso-BuC6H4, 136-7.degree.; 4-sec-BuC6H4, 115-16.degree.; 4-tert-BuC6H4, 125-6.degree.; 4-HO2CC6H4, 195-6.degree.; 4-PhCH2OC6H4, 130-1.degree.; 1-adamantyl, 152-3.degree.; and 2-thienyl, 148-9.degree.. Also prepd. were the following I (RCOCH2CH2 and m.p. given): 4-methyl-3-oxobutyl, 116-18.degree.; 4-methyl-3-oxohexyl, 101-3.degree.; 1,3-diphenyl-3-oxopropyl, 164-6.degree., 5-indanoylethyl, 134-6.degree.; 6-tetrahydronaphthoylethyl, 129-31.degree.; and 1-naphthoylethyl, 162-4.degree..

=> d ibib abs hitstr 7, 9-27

L6 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:430797 CAPLUS Full-text
DOCUMENT NUMBER: 141:7108
TITLE: Preparation of pyrazoles as modulators of peroxisome proliferator activated receptors (PPARs), in particular PPAR.gamma. agonists
INVENTOR(S): Huck, Jacques; Saladin, Regis; Sierra, Michael
PATENT ASSIGNEE(S): Carex SA, Fr.
SOURCE: PCT Int. Appl., 156 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043951	A1	20040527	WO 2003-EP311855	20031024
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003282051	A1	20040603	AU 2003-282051	20031024

PRIORITY APPLN. INFO.:

EP 2002-360298	A	20021024
EP 2002-360372	A	20021220
EP 2002-360373	A	20021220
US 2003-456954P	P	20030325
EP 2003-360070	A	20030611
EP 2003-360091	A	20030724
WO 2003-EP11855	W	20031024

OTHER SOURCE(S): MARPAT 141:7108
GI



I



II

AB Title compds. I [wherein R1 = H, CF3, (un)substituted alkyl, cycloalkyl, heterocyclyl, etc.; R2 = (un)substituted alkyl, amino, COH, etc.; n = 0-6; R11 and R12 = independently H, alkyl, CO2H and derivs., OH and derivs., NH2 and derivs., etc.; their analogs, derivs., solvates or salts] were prepd. for modulating peroxisome proliferator activated receptors (PPARs), in particular as PPAR.gamma. agonists, and for treating and/or preventing various diseases and conditions mediated by said nuclear receptors, including metabolic or cell proliferative disorders (no data). For example, 1-phenyl-3-(thiophen-2-yl)-1H-pyrazole-4-carboxaldehyde (prepn. given) was reacted with 1-(4-methoxyphenyl)ethanone in isopropanol to give II in 67% yield. II inhibited adipocyte differentiation induced by rosiglitazone by about 68%, demonstrating its antagonistic activity towards human PPAR.gamma.. II induced adipocyte differentiation (25% of rosiglitazone efficacy), proving its human PPAR.gamma. partial agonistic activity. I are useful for treating diabetes, atherosclerosis, hyperglycemia, dyslipidemia, obesity, syndrome X, insulin resistance, hypertension, neuropathy, microvascular diseases (e.g. retinopathy, nephropathy), macrovascular diseases (e.g. myocardial infarction, stroke, heart failure) in mammals.(no data).

IT 423728-18-1P, 1-(4-Ethylphenyl)-3-[1-phenyl-3-(pyridin-3-yl)-1H-pyrazol-4-yl]propenone
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PPAR.gamma. agonist; prepn. of pyrazoles as modulators of peroxisome proliferator activated receptors (PPARs), in particular PPAR.gamma. agonists)

RN 423728-18-1 CAPLUS

CN 2-Propen-1-one, 1-(4-ethylphenyl)-3-[1-phenyl-3-(3-pyridinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



L6 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:282325 CAPLUS Full-text

DOCUMENT NUMBER: 138:321285

TITLE: Preparation of quinazoline-2,4-diamines as MCH receptor antagonists

INVENTOR(S): Sekiguchi, Yoshinori; Kanuma, Kosuke; Omodera, Katsunori; Tran, Thuy-anh; Kramer, Bryan Aubrey; Beeley, Nigel Robert Arnold

PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 1171 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003028641	A2	20030410	WO 2002-US31059		20020930
WO 2003028641	A3	20030828			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2460594	A1	20030410	CA 2002-2460594		20020930
AU 2002334733	A1	20030414	AU 2002-334733		20020930
EP 1432693	A2	20040630	EP 2002-800388		20020930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
CN 1582281	A	20050216	CN 2002-823940		20020930
JP 2005523237	T	20050804	JP 2003-531977		20020930
US 2007037836	A1	20070215	US 2004-490996		20040803
PRIORITY APPLN. INFO.:			US 2001-326463P	P	20011001
			US 2001-326758P	P	20011002
			WO 2002-US31059	W	20020930

OTHER SOURCE(S): MARPAT 138:321285
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. QLYR1[Q = I, C(:NH)NH2; R1 = (un)substituted alkyl, alkenyl, cycloalkyl, etc.; L = II-IV (wherein R4 = H, alkyl; R5 = H, alkyl, alkyl substituted by a substituted carbocyclic aryl), etc.; Y = SO2, CO, (CH2)m; m = 0-1] which act as MCH receptor antagonists, and are useful for prophylaxis or treatment of obesity, obesity related disorders, anxiety, or depression, were prepd. Thus, hydrogenation of benzyl cis-[4-(4-dimethylaminoquinazolin-2-ylamino)cyclohexylmethyl]carbamate followed by reacting the resulting intermediate with 4-bromo-2- trifluoromethoxybenzaldehyde in the presence of NaBH(OAc)3 and AcOH in CH2Cl2, and treatment of the product with 4N HCl in EtOAc afforded 34% cis-V.2HCl which showed IC50 of 6 nM against MCH receptor.

IT 510742-20-8P 510744-45-3P 510750-46-6P
511262-80-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of quinazoline-2,4-diamines as MCH receptor antagonists)

RN 510742-20-8 CAPLUS

CN 1H-Pyrazole-4-acetamide, N-[cis-4-[[4-(dimethylamino)-2-quinazolinyl]amino]cyclohexyl]-4,5-dihydro-3-methyl-.alpha.-[2-[4-(1-methylethyl)phenyl]-2-oxoethyl]-5-oxo-1-phenyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 510744-45-3 CAPLUS
CN 1H-Pyrazole-4-acetamide, N-[[cis-4-[[4-(dimethylamino)-2-quinazolinyl]amino]cyclohexyl]methyl]-4,5-dihydro-3-methyl-.alpha.-[2-[4-(1-methylethyl)phenyl]-2-oxoethyl]-5-oxo-1-phenyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 510750-46-6 CAPLUS
CN 3H-Pyrazol-3-one, 4-[1-[[[[cis-4-[[4-(dimethylamino)-2-quinazolinyl]amino]cyclohexyl]methyl]amino]methyl]-3-[4-(1-methylethyl)phenyl]-3-oxopropyl]-2,4-dihydro-5-methyl-2-phenyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 511262-80-9 CAPLUS
CN 3H-Pyrazol-3-one, 4-[1-[[[cis-4-[[4-(dimethylamino)-2-quinazolinyl]amino]cyclohexyl]amino]methyl]-3-hydroxy-3-[4-(1-

methylethyl)phenyl]propyl]-2,4-dihydro-5-methyl-2-phenyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L6 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:220534 CAPLUS Full-text
DOCUMENT NUMBER: 136:263165
TITLE: Preparation of 1,2,3,4-tetrahydronaphthalenecarboxamide, 1,2,3,4-tetrahydroquinolinecarboxamide, indanecarboxamides, thiochromancarboxamide, and chromancarboxamide derivatives as C5a receptor antagonists and medicinal use thereof
INVENTOR(S): Nakamura, Mitsuharu; Kamahori, Takao; Ishibuchi, Seigo; Naka, Yoichi; Sumichika, Hiroshi; Itoh, Katsuhiko
PATENT ASSIGNEE(S): Mitsubishi Pharma Corporation, Japan
SOURCE: PCT Int. Appl., 415 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002022556	A1	20020321	WO 2001-JP7977		20010914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2001088045	A5	20020326	AU 2001-88045		20010914
CA 2422342	A1	20030313	CA 2001-2422342		20010914
EP 1318140	A1	20030611	EP 2001-967682		20010914
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
US 2004138223	A1	20040715	US 2003-380502		20030508
PRIORITY APPLN. INFO.:			JP 2000-280540	A	20000914
			JP 2000-386813	A	20001220
			WO 2001-JP7977	W	20010914

OTHER SOURCE(S): MARPAT 136:263165

GI



I

AB Amide derivs. represented by the following general formula [I; R1, R2, R3, R4 = H, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, or alkoxy, aryloxy, arylalkyloxy, (un)substituted acyloxy, halo, NO2, cyano, acyl SH, alkylthio, alkylsulfinyl, NH2, alkylamino, dialkylamino, cyclic amino, (un)substituted CONH2, alkoxycarbonyl, CO2h, acylamino, (un)substituted SO2NH2, haloalkyl; or any two of R1, R2, and R3 together with adjacent carbon atom form a ring; all a, b, c, d, and e is a carbon atom; or one or two of a, b, c, d, and e represent one or two nitrogen atom and the other represent C atoms; R4, R5, R6 = haloalkyloxy, groups listed in R1 - R4; A = H, (un)substituted cycloalkyl, aryl, heteroaryl, or cyclic amino; W1, W2 = a bond, (un)substituted C1-3 alkylene; Y = a single bond, O, CO, NR7, S, SO, SO2, CONR8, NR9CO (wherein R7, R8, R9 = H, (un)substituted alkyl); Z = a single bond, (un)substituted alkylene] or optically active isomers thereof or pharmaceutically acceptable salts thereof are prepd. These compds. are useful as preventives and remedies for diseases or syndromes caused by inflammation induced by C5a, e.g. immunol. diseases such as rheumatism and systemic lupus erythematosus, allergic diseases such as sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease and asthma, atherosclerosis, heart infarction, brain infarction, psoriasis, Alzheimer's disease and important organistic breakdown (e.g. pneumonia, nephritis, hepatitis, pancreatitis) induced by leukocyte activation caused by ischemic reperfusion, burn or surgical invasion. Moreover, they are useful as preventives and remedies for infection with bacteria and viruses mediated by C5a receptor. Thus, to a soln. of 3.3 g 1,2,3,4-tetrahydronaphthalene-1-carboxylic acid in 20 mL CH2Cl2 was added 2.1 mL SO2Cl2 and the resulting mixt. was refluxed for 3 h, concd. under reduced pressure, dissolved in 10 mL CH2Cl2, treated with a soln. of 5.1 g N-[(4-dimethylaminophenyl)methyl](4-isopropylphenyl)amine in 10 mL CH2Cl2 under ice-cooling, warmed to room temp., and stirred overnight to give N-[(4-dimethylaminophenyl)methyl]-N-(4-isopropylphenyl)-1,2,3,4- tetrahydronaphthalene-1-carboxamide (II). II inhibited the binding of [125I]-human C5a receptor to human histiocystic lymphoma cell line (U-937) with IC50 of 104 nm/mL. A tablet, a capsule, an injection soln., and an eyedrop formulation contg. II were prepd.

IT 405098-47-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of 1,2,3,4-tetrahydronaphthalenecarboxamide, 1,2,3,4-tetrahydroquinolinecarboxamide, indancarboxamides, thiochromancarboxamide, and chromancarboxamide derivs. as C5a receptor antagonists and medicinal use thereof)

RN 405098-47-7 CAPLUS

CN 1-Naphthalenecarboxamide, 1,2,3,4-tetrahydro-N-[4-(1-methylethyl)phenyl]-5-(phenylmethoxy)-N-[(1-phenyl-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX

NAME)



IT 405098-48-8P 405100-17-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 1,2,3,4-tetrahydronaphthalenecarboxamide, 1,2,3,4-tetrahydroquinolinecarboxamide, indancarboxamides, thiochromancarboxamide, and chromancarboxamide derivs. as C5a receptor antagonists and medicinal use thereof)

RN 405098-48-8 CAPLUS

CN 1-Naphthalenecarboxamide, 1,2,3,4-tetrahydro-5-hydroxy-N-[4-(1-methylethyl)phenyl]-N-[(1-phenyl-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 405100-17-6 CAPLUS

CN 1-Naphthalenecarboxamide, 1,2,3,4-tetrahydro-N-[4-(1-methylethyl)phenyl]-N-[(1-phenyl-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)



IT 405103-42-6, (4-Isopropylphenyl)[(1-phenylpyrazol-4-yl)methyl]amine
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of 1,2,3,4-tetrahydronaphthalenecarboxamide, 1,2,3,4-tetrahydroquinolinecarboxamide, indancarboxamides, thiochromancarboxamide, and chromancarboxamide derivs. as C5a receptor antagonists and medicinal use thereof)
RN 405103-42-6 CAPLUS
CN 1H-Pyrazole-4-methanamine, N-[4-(1-methylethyl)phenyl]-1-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:142660 CAPLUS Full-text
DOCUMENT NUMBER: 136:200179
TITLE: Preparation of N,N'-diarylurea derivatives as complement receptor C5a antagonists
INVENTOR(S): Ishibuchi, Seigo; Sumichika, Hiroshi; Itoh, Katsuhiko; Naka, Yoichi
PATENT ASSIGNEE(S): Welfide Corporation, Japan
SOURCE: PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002014265	A1	20020221	WO 2001-JP6902	20010810
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2418652	A1	20020221	CA 2001-2418652	20010810
AU 2001077751	A5	20020225	AU 2001-77751	20010810
EP 1308438	A1	20030507	EP 2001-955657	20010810
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003207939	A1	20031106	US 2003-343961	20030205
US 7105567	B2	20060912		

PRIORITY APPLN. INFO.: JP 2000-243290 A 20000810
WO 2001-JP6902 W 20010810

OTHER SOURCE(S): MARPAT 136:200179
GI



I

AB N,N'-diarylurea derivs. represented by the following general formula [I; R1, R2, R3 = H, (un)substituted alkyl, cycloalkyl, alkenyl, or alkynyl, HO, (un)substituted alkoxy, SH, (un)substituted alkylthio, halo, NO2, cyano, amino, alkylamino, cyclic amino, alkylsulfonyl, CONH2, acylamino, sulfamoyl, acyl, CO2H, alkoxycarbonyl, (un)substituted aryl or heteroaryl; D = a bond, (un)substituted alkylene; A = (un)substituted alkyl, cycloalkyl, aryl, or heteroaryl; R4, R5 = H, (un)substituted alkyl or alkoxy, HO, halo; R6 = H, (un)substituted alkyl or alkoxy, HO, halo; X = O, S] or pharmaceutically acceptable salts thereof are prepd. Because of having a C5a receptor antagonism, these compds. are useful as remedies and preventives for diseases or syndromes induced by C5a, e.g. autoimmune diseases such as rheumatism and systemic lupus erythematosus, allergic diseases such as sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease and asthma, atherosclerosis, cardiac infarction, brain infarction, psoriasis, Alzheimer's disease and serious organ injuries by the activation of leukocytes caused by ischemia, trauma, burn, surgical invasion, etc. (for example, pneumonia, nephritis, hepatitis and pancreatitis). Moreover, these compds. are also useful as remedies and preventives for bacterial and viral infections mediated by C5a receptor. Thus, to a soln. of (4-isopropylphenyl)[[1-(4-trifluoromethylbenzyl)pyrazol-4-yl]methyl]amine in toluene was added 2,6-

diisopropylphenyl isocyanate and stirred at room temp. overnight to give N'-(2,6-diisopropylphenyl)-N-(4-isopropylphenyl)-N-[[1-(4-trifluoromethylbenzyl)pyrazol-4-yl]methyl]urea. N'-(2,6- diisopropylphenyl)-N-[(4-dimethylaminophenyl)methyl]-N-(4- isopropylphenyl)urea 9/10 fumarate showed IC50 of 5 nmol/L for inhibiting the Ca2+ ion increase in C5a-simulated blood neutrophil. Pharmaceutical formulations, e.g. a capsule contg. N'-(2,6-diisopropylphenyl)-N-[(4- dimethylaminophenyl)methyl]-N-(4-fluorophenyl)urea.

IT 400865-51-2P, N-[[1-(4-Trifluoromethylphenyl)pyrazol-4-yl]methyl]-N-(4-isopropylphenyl)-N'-(2,6-diisopropylphenyl)urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of diarylurea derivs. as complement receptor C5a antagonists for therapeutic agents)

RN 400865-51-2 CAPLUS

CN Urea, N'-[2,6-bis(1-methylethyl)phenyl]-N-[4-(1-methylethyl)phenyl]-N-[[1-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:661400 CAPLUS Full-text
DOCUMENT NUMBER: 135:226990
TITLE: Preparation of 4-thiomethylpyrazoles as pesticides

INVENTOR(S): Wu, Tai-teh; Scribner, Andrew William
PATENT ASSIGNEE(S): Aventis CropScience SA, Fr.
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064651	A1	20010907	WO 2001-EP2306	20010301
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1263734	A1	20021211	EP 2001-919359	20010301
EP 1263734	B1	20060920		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003525275	T	20030826	JP 2001-563493	20010301
AT 340163	T	20061015	AT 2001-919359	20010301
US 2001053854	A1	20011220	US 2001-796651	20010302
US 6458744	B2	20021001		

PRIORITY APPLN. INFO.:	US 2000-186313P	P	20000302
	WO 2001-EP2306	W	20010301

OTHER SOURCE(S): MARPAT 135:226990
GI



AB The title compds. [I; Q = II, III; W = N, CR6; X1X2X3 = CF2CF2O, CF2OCF2, OCF2O; R1 = alkyl, haloalkyl, alkenyl, etc.; R2 = H, halo, (un)substituted NH2; R3, R6 = H, halo; R4 = H, haloalkyl; R5 = H, halo, haloalkyl, etc.; n = 0-2], useful as pesticides, were prepd. Thus, reacting 2-methylbutanethiol with 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano- 4-formylpyrazole with BF3.Et2O in 1,2-dichloroethane followed by addn. of Et3SiH, and then treating the resulting intermediate with DMF afforded I [Q = II; W = CCl; R1 = 2-methylbutyl; R2 = NH2; R3 = Cl; R4 = H; R5 = CF3; n = 0]. Biol. data for compds. I were given.

IT 358760-25-5P 358760-33-5P 358760-94-8P
358761-01-0P 358761-03-2P 358761-18-9P
358761-25-8P 358761-43-0P 358761-60-1P
358761-66-7P 358762-41-1P 358762-43-3P
358762-54-6P 358762-57-9P 358762-61-5P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 4-thiomethylpyrazoles as pesticides)

RN 358760-25-5 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[[[2-(1-methylethyl)phenyl]thio]methyl]- (9CI) (CA INDEX NAME)



RN 358760-33-5 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[[[4-(1,1-dimethylethyl)phenyl]thio]methyl]- (9CI) (CA INDEX NAME)



RN 358760-94-8 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 5-amino-1-[2-chloro-4-(trifluoromethyl)phenyl]-4-[[[2-(1-methylethyl)phenyl]thio]methyl]- (9CI) (CA INDEX NAME)



RN 358761-01-0 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 5-amino-1-[2-chloro-4-(trifluoromethyl)phenyl]-4-[[[4-(1,1-dimethylethyl)phenyl]thio]methyl]- (9CI) (CA INDEX NAME)



RN 358761-03-2 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 5-amino-1-[2-chloro-4-(trifluoromethyl)phenyl]-4-[[[4-(1-methylethyl)phenyl]thio]methyl]- (9CI) (CA INDEX NAME)



RN 358761-18-9 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 5-amino-1-[2-chloro-5-(trifluoromethyl)phenyl]-4-[[[2-(1-methylethyl)phenyl]thio]methyl]- (9CI) (CA INDEX NAME)



RN 358761-25-8 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 5-amino-1-[2-chloro-5-(trifluoromethyl)phenyl]-4-[[[4-(1,1-dimethylethyl)phenyl]thio]methyl]- (9CI) (CA INDEX NAME)



RN 358761-43-0 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 5-amino-4-[[[2-(1-methylethyl)phenyl]thio]methyl]-1-(2,4,6-trichlorophenyl)- .(9CI) (CA INDEX NAME)



RN 358761-60-1 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 5-amino-1-(2-bromo-4,6-dichlorophenyl)-4-[[[2-

(1-methylethyl)phenyl]thio]methyl]- (9CI) (CA INDEX NAME)



RN 358761-66-7 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 5-amino-1-(2-bromo-4,6-dichlorophenyl)-4-[[[4-(1,1-dimethylethyl)phenyl]thio]methyl]- (9CI) (CA INDEX NAME)



RN 358762-41-1 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[[[4-(1,1-dimethylethyl)phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 358762-43-3 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[[[4-(1-methylethyl)phenyl]sulfonyl]methyl]-(9CI) (CA INDEX NAME)



RN 358762-54-6 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 5-amino-1-[2,6-dichloro-4-(trifluoromethoxy)phenyl]-4-[[[2-(1-methylethyl)phenyl]sulfonyl]methyl]-(9CI) (CA INDEX NAME)



RN 358762-57-9 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 5-amino-1-[2-chloro-4-(trifluoromethyl)phenyl]-4-[[[4-(1,1-dimethylethyl)phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 358762-61-5 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 5-amino-1-(2-bromo-4,6-dichlorophenyl)-4-[[[4-(1-methylethyl)phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:620088 CAPLUS Full-text
DOCUMENT NUMBER: 135:357875
TITLE: 4-Functionally substituted 3-heterylpyrazoles: IV. 1-Phenyl-3-aryl(heteryl)-5-(4-pyrazolyl)-2-pyrazolines
AUTHOR(S): Bratenko, M. K.; Chornous, V. A.; Vovk, M. V.
CORPORATE SOURCE: Bukovinskaya State Medical Academy, Chernovtsy, 58000, Ukraine
SOURCE: Russian Journal of Organic Chemistry (Translation of Zhurnal Organicheskoi Khimii) (2001), 37(4), 556-559
CODEN: RJOCEQ; ISSN: 1070-4280
PUBLISHER: MAIK Nauka/Interperiodica Publishing
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 135:357875
GI



AB Formylpyrazoles I (R = Ph, 2-thienyl, 5-Me-2-furyl, 3-pyridyl) undergo aldol condensation reactions with Me ketones R1COMe (R1 = Ph, 4-FC6H4, 4-ClC6H4, 4-BrC6H4, 4-EtC6H4, 4-MeOC6H4, 2-furyl, 2-thienyl) to give diaryl

pyrazolylpropenones II (R = Ph, 2-thienyl, 5-Me-2-furyl, 3-pyridyl; R1 = Ph, 4-FC6H4, 4-ClC6H4, 4-BrC6H4, 4-EtC6H4, 4-MeOC6H4, 2-furyl, 2-thienyl) in 78-92% yields. II (R = Ph, 2-thienyl, 5-Me-2-furyl, 3-pyridyl; R1 = Ph, 4-FC6H4, 4-ClC6H4, 4-BrC6H4, 4-EtC6H4, 4-MeOC6H4, 2-furyl, 2-thienyl) undergo cyclocondensation with phenylhydrazine to give diarylpyrazolyl pyrazolines III (R = Ph, 2-thienyl, 5-Me-2-furyl, 3-pyridyl; R1 = Ph, 4-FC6H4, 4-ClC6H4, 4-BrC6H4, 4-EtC6H4, 4-MeOC6H4, 2-furyl, 2-thienyl) in 41-58% yields as potential components of luminescent composite dyes (no data). E.g., 4-bromoacetophenone was added to a soln. of I (R = Ph) in isopropanol; the mixt. was heated at 50.degree. and a 20% aq. sodium hydroxide soln. added; after 30 min. of stirring at 50.degree. and 3 h stirring at 18-20.degree., pptn. yielded II (R = Ph; R1 = 4-BrC6H4) in 92% yield. E.g., phenylhydrazine was added to a soln. of II (R = Ph; R1 = 4-BrC6H4) in acetic acid; the soln. was heated at reflux for 4 h to give III (R = Ph; R1 = 4-BrC6H4) in 53% yield.

IT 372190-43-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of diaryl pyrazolylpyrazolines as potential luminescent dye components by aldol condensation of aryl Me ketones with formylpyrazoles followed by cyclocondensation with phenylhydrazine)

RN 372190-43-7 CAPLUS
CN 2-Propen-1-one, 3-(1,3-diphenyl-1H-pyrazol-4-yl)-1-(4-ethylphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:583340 CAPLUS Full-text
DOCUMENT NUMBER: 131:235677
TITLE: Phenidone compound and silver halide color photographic paper containing the same
INVENTOR(S): Mikoshiba, Takashi; Yoshioka, Yasuhiro
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 55 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11246785	A	19990914	JP 1998-49809	19980302

PRIORITY APPLN. INFO.: JP 1998-49809 19980302
OTHER SOURCE(S): MARPAT 131:235677
GI



I



II

AB The Ag halide color photog. paper contains the phenidone compd. represented by a general formula I (L = alkylene; R1 = alkyl, aryl; R2, R3 = H, alkyl, aryl; R4-8 = H, substituent) and a cyan coupler represented by a general formula II (Za, Zb = -C(Rc):, -N:; Ra, Rb = electron withdrawing group having Hammett substituent const. .delta.p .gtoreq.0.20; Rc = H, substituent; X = H, coupling group). The photog. paper shows excellent color reprodn. and improved storage stability.

IT 243986-55-2 243986-57-4 243986-58-5
243986-59-6 243986-60-9 243986-63-2
243986-64-3 243986-65-4 243986-66-5
243986-72-3
RL: DEV (Device component use); USES (Uses)
(phenidone compd. in silver halide color photog. paper)

RN 243986-55-2 CAPLUS
CN 3-Pyrazolidinone, 4-[2-[4-cyclohexyl-2-(1,1-dimethylethyl)phenoxy]ethyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 243986-57-4 CAPLUS

CN 3-Pyrazolidinone, 1-phenyl-4-[2-[4-(1,1,3,3-tetramethylbutyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 243986-58-5 CAPLUS
CN 3-Pyrazolidinone, 4-[2-[2,4-bis(1,1,3,3-tetramethylbutyl)phenoxy]ethyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 243986-59-6 CAPLUS
CN 3-Pyrazolidinone, 4-[3-[2,4-bis(1,1-dimethylpropyl)phenoxy]propyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 243986-60-9 CAPLUS
CN 3-Pyrazolidinone, 4-[3-[2,4-bis(1,1-dimethylethyl)phenoxy]propyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 243986-63-2 CAPLUS
CN 3-Pyrazolidinone, 4-[4-[2,4-bis(1,1-dimethylpropyl)phenoxy]butyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 243986-64-3 CAPLUS

CN 3-Pyrazolidinone, 4-[2-[2-(1,1-dimethylethyl)-4-(octyloxy)phenoxy]ethyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 243986-65-4 CAPLUS
CN 3-Pyrazolidinone, 4-[2-[2,4-bis(1,1-dimethylethyl)phenoxy]propyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 243986-66-5 CAPLUS
CN 3-Pyrazolidinone, 4-[8-[2,4-bis(1,1-dimethylpropyl)phenoxy]octyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 243986-72-3 CAPLUS
CN 3-Pyrazolidinone, 4-[2-[2,4-bis(1,1-dimethylethyl)phenoxy]ethyl]-1-[3-(hexadecyloxy)phenyl]- (9CI) (CA INDEX NAME)



IT 243986-53-0P 243986-54-1P
RL: DEV (Device component use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)
(phenidone compd. in silver halide color photog. paper)
RN 243986-53-0 CAPLUS
CN 3-Pyrazolidinone, 4-[2-[2,4-bis(1,1-dimethylpropyl)phenoxy]ethyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 243986-54-1 CAPLUS
CN 3-Pyrazolidinone, 4-[2-[2,4-bis(1,1-dimethylethyl)phenoxy]ethyl]-1-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:659311 CAPLUS Full-text
DOCUMENT NUMBER: 125:300995
TITLE: Preparation of 2-pyrazoline derivatives as herbicides
INVENTOR(S): Araino, Nobuyuki; Miura, Juzo; Oda, Yoshiki; Nishioka, Hitoshi
PATENT ASSIGNEE(S): Nihon Nohyaku Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 63 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08217777	A	19960827	JP 1995-46427	19950210

PRIORITY APPLN. INFO.: JP 1995-46427 19950210
OTHER SOURCE(S): MARPAT 125:300995

GI



I

AB The title compds. [I; R = (un)substituted alkyl or alkenyl or Ph or pyridinyl, etc.; R1, R2 = H, (un)substituted alkyl or alkenyl, etc.; X = halo, NO2, (un)substituted alkyl or amino, etc.; n = 0-5; Z = CH2O] and their intermediates (Z = O, :CH2; others are same as above) are claimed. Herbicides contg. I are effective against Amaranthus lividus, Scirpus juncoides, and Monochoria vaginalis. Thus, trimethylsulfonium iodide was treated with NaH and then reacted with 4-benzoylmethyl-4-ethyl-3-methyl-1- phenyl-2-pyrazolin-5-one to give 55% a mixt. of diastereoisomers I (R = Ph, R1 = Et, R2 = Me, X = H, n = 5, Z = CH2O) (II). Herbicides contg. II at 3 kg/ha preemergence showed 100% herbicidal effect for Amaranthus lividus and Scirpus juncoides.

IT 182873-93-4P 182873-94-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of pyrazoline derivs. as herbicides)

RN 182873-93-4 CAPLUS

CN 3H-Pyrazol-3-one, 4-ethyl-4-[2-(3-ethylphenyl)-2-oxoethyl]-2,4-dihydro-5-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 182873-94-5 CAPLUS

CN 3H-Pyrazol-3-one, 4-ethyl-4-[2-(4-ethylphenyl)-2-oxoethyl]-2,4-dihydro-5-methyl-2-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:171879 CAPLUS Full-text
DOCUMENT NUMBER: 124:220541
TITLE: Corticotropin-releasing factor antagonists for treatment of stress-related disorders
INVENTOR(S): Bright, Gene M.; Chen, Yuhpyng L.; Welch, Willard M., Jr.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: Eur. Pat. Appl., 27 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 691128	A1	19960110	EP 1995-201475	19950606
EP 691128	B1	20021211		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5646152	A	19970708	US 1994-259835	19940615
AT 229334	T	20021215	AT 1995-201475	19950606
PT 691128	T	20030228	PT 1995-201475	19950606
ES 2186704	T3	20030516	ES 1995-201475	19950606
CA 2151674	A1	19951216	CA 1995-2151674	19950613
CA 2151674	C	19990622		
AU 9521691	A	19951221	AU 1995-21691	19950614
AU 701963	B2	19990211		
JP 08003041	A	19960109	JP 1995-170453	19950614
HU 71602	A2	19960129	HU 1995-1738	19950614
ZA 9504921	A	19961217	ZA 1995-4921	19950614
CZ 294696	B6	20050216	CZ 1995-1537	19950614
US 6200979	B1	20010313	US 1997-796096	19970205

PRIORITY APPLN. INFO.: US 1994-259835 A 19940615

AB Substituted pyrazoles and pyrazolopyrimidines (Markush structures is given) have ACTH-releasing factor antagonist activity and are useful in the treatment of a variety of stress-related disorders (no data).

IT 174569-91-6 174569-92-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ACTH-releasing factor antagonists for treatment of stress-related disorders)

RN 174569-91-6 CAPLUS

CN 1-Naphthaleneethanol, 2-[[1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-(dimethylamino)-3-ethyl-1H-pyrazol-4-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 174569-92-7 CAPLUS
CN 1-Naphthaleneethanol, 2-[[5-(dimethylamino)-3-(methylthio)-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-yl]methoxy]- (9CI) (CA INDEX NAME)



closest ant.

L6 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1994:408893 CAPLUS Full-text
DOCUMENT NUMBER: 121:8893
TITLE: Phenyl-substituted acrylate ester agrochemical fungicides
INVENTOR(S): Mueller, Bernd; Roehl, Franz; Koenig, Hartmann; Sauter, Hubert; Lorenz, Gisela; Ammermann, Eberhard
PATENT ASSIGNEE(S): BASF A.-G., Germany
SOURCE: Eur. Pat. Appl., 86 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 581095	A2	19940202	EP 1993-111103	19930712
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
CA 2100546	A1	19940125	CA 1993-2100546	19930714
JP 06211748	A	19940802	JP 1993-181305	19930722
AU 9342121	A	19940127	AU 1993-42121	19930723
AU 660226	B2	19950615		
HU 66105	A2	19940928	HU 1993-2150	19930723
ZA 9305332	A	19950123	ZA 1993-5332	19930723

PRIORITY APPLN. INFO.: DE 1992-4224457 A 19920724
OTHER SOURCE(S): MARPAT 121:8893
GI



I



II

AB The title compds. [I; B = (un)substituted alkyl, C1-4 (un)substituted alkenyl, (un)substituted alkynyl, etc.; R1, R2 = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, etc.; X, Y = H, halogen, CN, NO2, haloalkyl, alkyl, alkenyl, alkynyl, heteroaryl, heterocyclyl, etc.], useful as agrochem. fungicides, are prepd. and I-contg. formulations presented. Thus, Me .alpha.-(2-hydroxyphenyl)-.beta.-methoxyacrylate was condensed with phenacyl bromide, producing acrylate II, m.p. 76.degree., which demonstrated 90% inhibitory activity against Plasmopara viticola at 250 ppm.

IT 154594-98-6P 154594-99-7P 154595-00-3P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as agrochem. fungicide)

RN 154594-98-6 CAPLUS

CN Benzeneacetic acid, .alpha.-(methoxymethylene)-2-[(1-phenyl-1H-pyrazol-4-yl)methoxy]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 154594-99-7 CAPLUS

CN Benzeneacetic acid, .alpha.-(methoxymethylene)-2-[(5-methyl-1-phenyl-1H-pyrazol-4-yl)methoxy]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 154595-00-3 CAPLUS

CN Benzeneacetic acid, 2-[(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)methoxy]-.alpha.-(methoxymethylene)-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L6 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1994:323576 CAPLUS Full-text
DOCUMENT NUMBER: 120:323576
TITLE: Heteroaromatic compounds and plant-protecting agents containing them
INVENTOR(S): Mueller, Bernd; Sauter, Hubert; Wingert, Horst; Koenig, Hartmann; Roehl, Franz; Ammermann, Eberhard; Lorenz, Gisela
PATENT ASSIGNEE(S): BASF A.-G., Germany
SOURCE: Eur. Pat. Appl., 124 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 579071	A2	19940119	EP 1993-110679	19930705
EP 579071	A3	19970528		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
JP 06184096	A	19940705	JP 1993-161424	19930630
JP 3217191	B2	20011009		
JP 2002053558	A	20020219	JP 2001-144159	19930630
IL 106292	A	19980816	IL 1993-106292	19930709
CA 2100308	A1	19940117	CA 1993-2100308	19930712
AU 9341937	A	19940120	AU 1993-41937	19930715
AU 671457	B2	19960829		
ZA 9305108	A	19950116	ZA 1993-5108	19930715
HU 68645	A2	19950728	HU 1993-2034	19930715
HU 214281	B	19980302		
US 5663185	A	19970902	US 1995-407371	19950320
US 5672616	A	19970930	US 1996-720180	19960925
US 5736566	A	19980407	US 1997-888899	19970707
US 5817682	A	19981006	US 1997-949761	19971014
US 5962489	A	19991005	US 1998-141331	19980827
PRIORITY APPLN. INFO.:			DE 1992-4223357	A 19920716
			JP 1993-161424	A3 19930630
			US 1993-91265	B3 19930715
			US 1995-407371	B3 19950320
			US 1995-500138	A3 19950710

US 1997-888899 A3 19970707
US 1997-949761 A3 19971014

OTHER SOURCE(S): MARPAT 120:323576

GI



I



II

AB Heteroarom. compds. and plant-protecting agents contg. them are claimed. Such more narrowly claimed compds. are 3-pyrazoleacetates, 3-oxazoleacetates, 4-isoxazoleacetates, etc. Example compds. are Me .alpha.-(hydroxyimino)-5-[(2-methylphenoxy)methyl]-4-thiazoleacetate (I) or Me 4-[(2-cyclopropyl-1-oxopropoxy)methyl]-.alpha.-(methoxyimino)-5- isoxazoleacetate (II).

IT 155298-26-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as plant-protecting agent fungicide)

RN 155298-26-3 CAPLUS

CN 1H-Pyrazole-5-acetic acid, .alpha.-(methoxyimino)-4-[[2-methyl-4-[1-[(2-propenyloxy)imino]ethyl]phenoxy]methyl]-1-phenyl-, methyl ester, (E,E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



L6 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1990:601214 CAPLUS Full-text
DOCUMENT NUMBER: 113:201214
TITLE: Direct-positive color photographic material
INVENTOR(S): Deguchi, Hisayasu; Ichijima, Yasushi
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 35 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02061636	A	19900301	JP 1988-212080	19880826

PRIORITY APPLN. INFO.: JP 1988-212080 19880826

GI



I

AB In a photog. material comprising a support and .gtoreq.1 emulsion layer contg. unprefogged internal latent image-type Ag halide grains, the emulsion layers contain .gtoreq.1 A{(L1)vB1}m(L2)wB2 [A = a group splitting off {(L1)vB1}m(L2)wB2 upon reaction with an oxidized developing agent; a, v, w = 0, 1; L1, L2 = a linking group capable of splitting off during development; B1, B2 = a residue capable of reducing the oxidn. products of the developing agent] and .gtoreq.1 compd. having the formula I [M = H, a cation, a protective group for mercapto group split off by alkali; X = atoms required to complete a 5- or 6-membered heterocyclic ring; R = alkylene, alkenylene, arylene; Z = a polar substituent; Y = various divalent atoms and groups; R1 = H, other substituent; n = 0, 1; m = 0, 1, 2].

IT 130339-55-8
RL: USES (Uses)
(direct-pos. photog. material using)

RN 130339-55-8 CAPLUS

CN 2-Naphthalenecarboxamide, N-[4-[2,4-bis(1,1-dimethylpropyl)phenoxy]butyl]-1-hydroxy-4-[[4-[[4-hydroxy-3-(1,1,3,3-tetramethylbutyl)phenoxy]methyl]-3-methyl-1-(4-nitrophenyl)-1H-pyrazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



L6 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1990:523724 CAPLUS Full-text

DOCUMENT NUMBER: 113:123724

TITLE: Color photographic material

INVENTOR(S): Ichijima, Yasushi; Ogawa, Akira

PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 30 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02016541	A	19900119	JP 1988-166030	19880705

PRIORITY APPLN. INFO.: JP 1988-166030 19880705

AB The title material contains .gtoreq.1 development inhibitor releasing yellow coupler of the formula AL1L2DI [A = a group cleavable from L1L2DI by reaction with an oxidized developer; L1 = a group cleavable from L2DI after cleavage from A; L2 = a group cleavable from DI after cleavage from L1; DI = a development inhibitor or its precursor], and .gtoreq.1 hydrophobic 2-equiv. yellow coupler (mol. wt. 450-720) of the formula R1COCXHCONHAr [R1 = tertiary alkyl, arom.; Ar = arom.; X = group to be released upon reaction with an oxidized developer; a dimer may be formed with R1, Ar, or X becoming a divalent connecting group]. The material shows improved image sharpness.

IT 129340-38-1
RL: USES (Uses)
(photog. development-inhibitor-releasing yellow coupler, color material contg., with improved image sharpness)

RN 129340-38-1 CAPLUS

CN Benzoic acid, 4-chloro-3-[[3-(4-methoxyphenyl)-2-[[3-methyl-4-[[2-[[(5-methyl-1,3,4-oxadiazol-2-yl)thio]methyl]phenoxy]methyl]-1-phenyl-1H-pyrazol-5-yl]oxy]-1,3-dioxopropyl]amino]-, dodecyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 21 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1990:449675 CAPLUS Full-text
DOCUMENT NUMBER: 113:49675
TITLE: Color film containing improved development inhibitor-releasing compound
INVENTOR(S): Nakajo, Kiyoshi; Ichijima, Yasushi; Sakagami, Megumi
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 37 pp.

CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01266540	A	19891024	JP 1988-95313	19880418

PRIORITY APPLN. INFO.: JP 1988-95313 19880418

AB The title full-color photog. material contains .gtoreq.1 development inhibitor-releasing compd., and has a total photosensitive layer thickness at development of .ltoreq.40 .mu.m. The material has improved sharpness.

IT 128103-60-6
RL: USES (Uses)
(photog. development-inhibitor-releasing coupler, color film contg., with improved sharpness)

RN 128103-60-6 CAPLUS

CN Benzoic acid, 3,3'-[[2-[[4-[[2-[[[5-[(2-methoxy-1-methyl-2-oxoethyl)thio]-1,3,4-thiadiazol-2-yl]thio]methyl]phenoxy]methyl]-3-methyl-1-(4-nitrophenyl)-1H-pyrazol-5-yl]oxy]-1,3-dioxo-1,3-propanediyl]diimino]bis[4-chloro-, didodecyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L6 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1988:560433 CAPLUS Full-text
DOCUMENT NUMBER: 109:160433
TITLE: Development inhibitor-releasing coupler for silver halide color photographic material
INVENTOR(S): Ishige, Osamu; Kida, Shuji; Nakagawa, Satoshi
PATENT ASSIGNEE(S): Konica Co., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 28 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63027840	A	19880205	JP 1986-170762	19860722

PRIORITY APPLN. INFO.: JP 1986-170762 19860722

AB A color photog. material having improved image sharpness and color quality and diminished contamination of developing soln. is claimed which comprises .gtoreq.1 Ag halide emulsion layer contg. a photog. useful group precursor and a compd. which releases a reactive group or an agent forming a photog. useful group through reaction with the photog. useful group precursor during processing.

IT 116826-62-1
RL: USES (Uses)
(photog. development inhibitor-releasing coupler)
RN 116826-62-1 CAPLUS
CN 2-Naphthalenecarboxamide, 4-[[4-[[[2-butoxy-4-(1,1,3,3-tetramethylbutyl)phenyl]thio]methyl]-3-methyl-1-phenyl-1H-pyrazol-5-yl]oxy]-1-hydroxy-N-[2-(tetradecyloxy)phenyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 23 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1981:150018 CAPLUS Full-text
DOCUMENT NUMBER: 94:150018
TITLE: Pyrazolidine derivatives: a comparative study of their effects on platelet aggregation
AUTHOR(S): Cepelak, V.; Cepelakova, Hana; Brunova, Bohumila; Kuchar, M.; Roubal, Z.
CORPORATE SOURCE: Fac. Med., Charles Univ., Pilsen, Hung.

SOURCE: Folia Haematologica (Leipzig) (1979), 106(5-6), 839-48
CODEN: FOHEAW; ISSN: 0323-4347
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Phenylbutazone [50-33-9] and 3-oxoalkyl substituted diphenyldioxopyrazolidines I (R = H or CO2H; X = H, Me, Et, OH, halo, etc.) such as kebuzone [853-34-9], tribuzone [13221-27-7], and benzopyrazone [3878-14-6] inhibited primary and secondary platelet aggregation in vitro and ex vivo. The ex vivo effect of these compds. was dependent on the elimination kinetics and blood concn. of the compds. Structure-activity studies indicated that an increase in the alkyl side chain length attached to the Ph ring of I caused a decrease in platelet aggregation inhibitory activity, whereas a halide substitution in the meta position of the pH ring of I increased the inhibitory activity.

IT 20358-35-4 20358-37-6 20358-38-7
20567-54-8
RL: BIOL (Biological study)
(blood platelet aggregation inhibition by, structure in relation to)

RN 20358-35-4 CAPLUS
CN 3,5-Pyrazolidinedione, 4-[3-[4-(1-methylethyl)phenyl]-3-oxopropyl]-1,2-diphenyl- (9CI) (CA INDEX NAME)



RN 20358-37-6 CAPLUS
CN 3,5-Pyrazolidinedione, 4-[3-[4-(2-methylpropyl)phenyl]-3-oxopropyl]-1,2-diphenyl- (9CI) (CA INDEX NAME)



RN 20358-38-7 CAPLUS
CN 3,5-Pyrazolidinedione, 4-[3-[4-(1-methylpropyl)phenyl]-3-oxopropyl]-1,2-diphenyl- (9CI) (CA INDEX NAME)



RN 20567-54-8 CAPLUS
CN 3,5-Pyrazolidinedione, 4-[3-(4-ethylphenyl)-3-oxopropyl]-1,2-diphenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 24 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1977:5366 CAPLUS Full-text
DOCUMENT NUMBER: 86:5366
TITLE: Chemistry of heteroanalogs of isoflavones. IV. Synthesis of pyrazole analogs of isoflavones
AUTHOR(S): Khilya, V. P.; Grishko, L. G.; Zhul, T. I.
CORPORATE SOURCE: Kiev. Gos. Univ. im. Shevchenko, Kiev, USSR
SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1976), (8), 1108-11
CODEN: KGSSAQ; ISSN: 0132-6244
DOCUMENT TYPE: Journal
LANGUAGE: Russian
OTHER SOURCE(S): CASREACT 86:5366
GI



I



II



III



IV

AB Pyrazole analogs of isoflavones I (R1 = CO2Et, CF3, H, R2 = hexyl, Cl, R3 = H, Me, COMe, Et) and II (R2 = H, Me, R3 = Me, H, COMe) were obtained in 71-98% yields by cyclization of the corresponding acetophenone derivs. III, and IV with ClCOCO2Et, (CF3CO)2O, HCO2Me in the presence of NaOCMe3 or by heating with HC(OEt)3 in pyridine.

IT 61033-96-3P 61033-98-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and cyclization of)

RN 61033-96-3 CAPLUS

CN Ethanone, 1-(5-hexyl-2,4-dihydroxyphenyl)-2-(1-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



RN 61033-98-5 CAPLUS

CN Ethanone, 1-(5-hexyl-2-hydroxy-4-methoxyphenyl)-2-(1-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



L6 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1974:133338 CAPLUS Full-text

DOCUMENT NUMBER: 80:133338

TITLE: 4-Substituted-1,2-diphenyl-3,5-dioxopyrazolidines

AUTHOR(S): Fisnerova, L.; Kakac, B.; Nemecek, O.

CORPORATE SOURCE: Vyzk. Ustav Farm. Biochem., Prague, Czech.

SOURCE: Collection of Czechoslovak Chemical Communications (1974), 39(2), 624-33
CODEN: CCCCAK; ISSN: 0010-0765

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.

AB Four groups of title compds. with potential antiinflammatory activity were prepd. Thus, Na salt of 1,2-diphenyl-3,5-dioxopyrazolidine was treated at

120.degree. in DMF with R1CH2NMe2 or R2COCH:CHR3 to give, resp., I and II (R = Me, Ph, CO2X, aliph. chain, arom. or heterocyclic group). Similarly, some pharmacol. active III [R4 = (CH2)2-COMe, (CH2)2COPh, (CH2)2COCMe3, (CH2)3Me] were treated as above with ClCH2CO2Et or Cl(CH2)2NMe2 and the product worked up with HCl to yield IV [R4 = as above, R5 = CH2CO2H, (CH2)2NMe2.HCl]. In the 4th group, contg. an indole ring, V was prepd. by heating at 80.degree. in anhyd. PhMe in the presence of H3PO4 N-(4-chlorobenzoyl)-N-(4-methoxyphenyl)hydrazine-HCl with 1,2-diphenyl-3,5-dioxo-4-(3-oxobutyl)pyrazoldine or its 4-carboxymethyl deriv. to give, resp., V (R6 = H) and V (R6 = CH2CO2H). Some compds. of the II group proved pharmacol. most promising.

IT 52479-07-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 52479-07-9 CAPLUS

CN 3,5-Pyrazolidinedione, 4-[3-[4-(1,1-dimethylethyl)phenyl]-1-(2-furanyl)-3-oxopropyl]-1,2-diphenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 26 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1969:512852 CAPLUS Full-text

DOCUMENT NUMBER: 71:112852

TITLE: Benzopyrazone [4-(2-benzoylethyl)-1,2-diphenyl-3,5-pyrazolidinedione] derivatives. II

AUTHOR(S): Brunova, B.; Musil, V.; Horakova, Z.; Nemecek, O.

CORPORATE SOURCE: Vyzk. Ustav Farm. Biochem., Prague, Czech.

SOURCE: Cesko-Slovenska Farmacie (1969), 18(1), 28-32
CODEN: CKFRAY; ISSN: 0009-0530

DOCUMENT TYPE: Journal

LANGUAGE: Czech

GI For diagram(s), see printed CA Issue.

AB 4-Substituted-2-benzoylethyl-1,2-diphenyl-3,5-pyrazolidinediones (I) were prepd. by reaction of a Mannich base II and the Na salt of 1,2-diphenyl-3,5-pyrazolidinedione (III). The mixt. of II and III was heated in methanol, Me2SO4 in methanol added, and the mixt. refluxed 3-4 hrs. and worked up. The following I were prepd. (R, m.p., and % yield given): p-Me, 151-2.degree. (95% EtOH), 50.2; p-Et, 130-2.degree. (EtOH), 53.5; p-Pr, 140-2.degree. (70% EtOH), 16.5; p-iso-Pr, 122-3.degree. (80% EtOH), 38; p-Bu, 122-4.degree. (EtOH), 41; p-tert-Bu, 126-7.degree. (EtOH), 36.4; p-sec-Bu, 116-17.degree. (EtOH), 11.4; p-iso-Bu, 136-7.degree. (EtOH), 52.3; 2.5-di-Me, 129-30.degree. (EtOH), 47; 3,4-di-Me, 148.degree. (EtOH), 36.2; 2,4,6-Me3, 123.5.degree. (EtOH), 49.3;

4,3-ClMe, 138-9.degree. (EtOH), 55.5; 2,5-ClMe, 123-5.degree. (EtOH), 51; 3,4-BrMe, 131-3.degree. (benzene-n-hexane), 38; 3-F3C, 128-30.degree. (EtOH), 30; and the following Ia: 5,6,7,8-tetrahydro- .alpha.-naphthyl, 162-4.degree. (EtOH), 23.3; 5,6,7,8-tetrahydro-.beta.- naphthyl, 130-1.degree. (EtOH) 24; and 5-(2,3-dihydro)indenyl, 134-6.degree. (EtOH) 19. The following RCOCH2CH2NMe2.HCl were prepd. (R, m.p., and % yield given): p-tolyl, 176-8.degree. (EtOH-acetone), 51; p-ethylphenyl, 149-50.degree. (EtOH-acetone), 58.2; p-propylphenyl, 140-1.degree. (EtOH-ether), 60.1; p-isopropylphenyl, 161-3.degree. (EtOH-acetone), 42.8; p-butylphenyl, 142-3.degree. (EtOH-acetone), 31; p-tert-butylphenyl, 163-5.degree. (EtOH-ether), 67; p-sec-butylphenyl, 153-5.degree. (EtOH-ether), 43.5; p-isobutylphenyl, 160-2.degree. (EtOH-ether), 38; 2,5-dimethylphenyl, 151-3.degree. (EtOH-acetone), 46.8; 3,4-dimethylphenyl, 193-5.degree. (EtOH-acetone), 87.3; mesityl, 157-9.degree. (EtOH-acetone), 51; .alpha.-naphthyl, 165-6.degree. (EtOH-acetone), 51.7; 5,6,7,8-tetrahydro-.beta.-naphthyl, 165-6.degree. (EtOH-acetone), 31.7; 5-(2,3-dihydro)indenyl, 178.degree. (EtOH-acetone), 55.4; 3-methyl-4-chlorophenyl, 185-7.degree. (EtOH), 74.3; 2-chloro-5-methylphenyl, 161-3.degree. (EtOH), 47.5; 3-bromo-4-methylphenyl, 186-7.degree. (EtOH), 88; and 3-trifluoromethylphenyl, 136-7.degree. [EtOH-iso-Pr2O], 55.7. Some show slight antiinflammatory activity.

IT 20358-35-4P 20358-36-5P 20358-37-6P
20358-38-7P 20358-39-8P 20567-54-8P
23934-90-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 20358-35-4 CAPLUS

CN 3,5-Pyrazolidinedione, 4-[3-[4-(1-methylethyl)phenyl]-3-oxopropyl]-1,2-diphenyl- (9CI) (CA INDEX NAME)



RN 20358-36-5 CAPLUS

CN 3,5-Pyrazolidinedione, 4-[2-(p-butylbenzoyl)ethyl]-1,2-diphenyl- (8CI) (CA INDEX NAME)



RN 20358-37-6 CAPLUS
CN 3,5-Pyrazolidinedione, 4-[3-[4-(2-methylpropyl)phenyl]-3-oxopropyl]-1,2-diphenyl- (9CI) (CA INDEX NAME)



RN 20358-38-7 CAPLUS
CN 3,5-Pyrazolidinedione, 4-[3-[4-(1-methylpropyl)phenyl]-3-oxopropyl]-1,2-diphenyl- (9CI) (CA INDEX NAME)



RN 20358-39-8 CAPLUS
CN 3,5-Pyrazolidinedione, 4-[2-(p-tert-butylbenzoyl)ethyl]-1,2-diphenyl-(8CI) (CA INDEX NAME)



RN 20567-54-8 CAPLUS
CN 3,5-Pyrazolidinedione, 4-[3-(4-ethylphenyl)-3-oxopropyl]-1,2-diphenyl-(9CI) (CA INDEX NAME)



RN 23934-90-9 CAPLUS
CN 3,5-Pyrazolidinedione, 1,2-diphenyl-4-[2-(p-propylbenzoyl)ethyl]- (8CI) (CA INDEX NAME)



L6 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1968:496713 CAPLUS Full-text
DOCUMENT NUMBER: 69:96713
TITLE: 4-Substituted 1,2-diphenyl-3,5-dioxopyrazolidines
PATENT ASSIGNEE(S): SPOFA, United Pharmaceutical Works
SOURCE: Brit., 6 pp.
CODEN: BRXXAA
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1117679		19680619	GB 1966-51960	19661121
CZ 145219			CZ	
DE 1620440			DE	
FR 1513442			FR	

US 3519640 19700707 US 19661221
PRIORITY APPLN. INFO.: CS 19651223

GI For diagram(s), see printed CA Issue.

AB Pyrazolidines and their salts with antiinflammatory, analgesic, fibrinolytic, antirheumatic and uricosurgical properties were prepd. To 12.5 g. Na in 750 ml. MeOH is added 126 g. 1,2-diphenyl-3,5- dioxopyrazolidine, the whole added to a soln. of 78.5 g. 1-dimethylamino-4,4-dimethyl-3-pentanone in 200 ml. MeOH, the mixt. refluxed and stirred as a soln. of 62.8 g. Me2SO4 in 150 ml. MeOH is added dropwise over 40-50 min., and the mixt. refluxed and stirred 3 hrs. and worked up to yield 70 g. 1,2-diphenyl-3,5-dioxo-4-(4,4-dimethyl-3 -oxopentyl)pyrazolidine, m. 139-40.degree. (dil. HOAc). Also prepd. were the following I (R and m.p. given): 2-FC6H4, 175-7.degree. (EtOH); 3-FC6H4, 149-50.degree.; 4-FC6H4, 106-7.degree.; 2-IC6H4, 135-7.degree.; 3-IC6H4, 114-15.degree.; 4-IC6H4, 151-2.degree.; 2-ClC6H4, 125-7.degree.; 3-ClC6H4, 119-20.degree.; 2-BrC6H4, 138-9.degree.; 3-BrC6H4, 119-21.degree.; 3-F3CC6H4, 128-30.degree. (EtOH); 2,5-ClMeC6H3, 118-20.degree. (EtOH); 3,4-BrMeC6H3, 146-8.degree.; 4-MeSC6H4, 126-7.degree.; 2,5-Me2C6H3, 129-30.degree.; 3,4-Me2C6H3, 147-8.degree.; 2,4,6-Me3C6H2, 123-5.degree.; 4-EtC6H4, 130-2.degree.; 4-iso-PrC6H4, 122-3.degree.; 4-BuC6H4, 122-4.degree.; 4-iso-BuC6H4, 136-7.degree.; 4-sec-BuC6H4, 115-16.degree.; 4-tert-BuC6H4, 125-6.degree.; 4-HO2CC6H4, 195-6.degree.; 4-PhCH2OC6H4, 130-1.degree.; 1-adamantyl, 152-3.degree.; and 2-thienyl, 148-9.degree.. Also prepd. were the following I (RCOCH2CH2 and m.p. given): 4-methyl-3-oxobutyl, 116-18.degree.; 4-methyl-3-oxohexyl, 101-3.degree.; 1,3-diphenyl-3-oxopropyl, 164-6.degree., 5-indanoylethyl, 134-6.degree.; 6-tetrahydronaphthoylethyl, 129-31.degree.; and 1-naphthoylethyl, 162-4.degree..

IT 20358-35-4P 20358-36-5P 20358-37-6P
20358-38-7P 20358-39-8P 20567-54-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 20358-35-4 CAPLUS

CN 3,5-Pyrazolidinedione, 4-[3-[4-(1-methylethyl)phenyl]-3-oxopropyl]-1,2-diphenyl- (9CI) (CA INDEX NAME)



RN 20358-36-5 CAPLUS

CN 3,5-Pyrazolidinedione, 4-[2-(p-butylbenzoyl)ethyl]-1,2-diphenyl- (8CI) (CA INDEX NAME)



RN 20358-37-6 CAPLUS
CN 3,5-Pyrazolidinedione, 4-[3-[4-(2-methylpropyl)phenyl]-3-oxopropyl]-1,2-diphenyl- (9CI) (CA INDEX NAME)



RN 20358-38-7 CAPLUS
CN 3,5-Pyrazolidinedione, 4-[3-[4-(1-methylpropyl)phenyl]-3-oxopropyl]-1,2-diphenyl- (9CI) (CA INDEX NAME)



RN 20358-39-8 CAPLUS
CN 3,5-Pyrazolidinedione, 4-[2-(p-tert-butylbenzoyl)ethyl]-1,2-diphenyl-
(8CI) (CA INDEX NAME)



RN 20567-54-8 CAPLUS
CN 3,5-Pyrazolidinedione, 4-[3-(4-ethylphenyl)-3-oxopropyl]-1,2-diphenyl-
(9CI) (CA INDEX NAME)




```
=> s l6 and metabolic disorder
         235888 METABOLIC
             26 METABOLICS
         235909 METABOLIC
                   (METABOLIC OR METABOLICS)
         262014 DISORDER
         205038 DISORDERS
         415785 DISORDER
                   (DISORDER OR DISORDERS)
          33559 METABOLIC DISORDER
                   (METABOLIC(W)DISORDER)
L7             2 L6 AND METABOLIC DISORDER

=> s l6 and diabete
             58 DIABETE
         127789 DIABETES
         127793 DIABETE
                   (DIABETE OR DIABETES)
L8             6 L6 AND DIABETE

=> d l6 and atherosclerosis
'AND' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'
'ATHEROSCLEROSIS' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
```

```
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):end

=> s l6 and atherosclerosis
         55617 ATHEROSCLEROSIS
L9           6 L6 AND ATHEROSCLEROSIS

=> s l6 and cardiovascular disorder
        100541 CARDIOVASCULAR
             4 CARDIOVASCULARS
        100544 CARDIOVASCULAR
                 (CARDIOVASCULAR OR CARDIOVASCULARS)
        262014 DISORDER
        205038 DISORDERS
        415785 DISORDER
                 (DISORDER OR DISORDERS)
          2165 CARDIOVASCULAR DISORDER
```

(CARDIOVASCULAR(W)DISORDER)
L10 1 L6 AND CARDIOVASCULAR DISORDER

=> s l6 and cardiovascular
100541 CARDIOVASCULAR
4 CARDIOVASCULARS
100544 CARDIOVASCULAR
(CARDIOVASCULAR OR CARDIOVASCULARS)
L11 3 L6 AND CARDIOVASCULAR

=> d abs tot

L11 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
GI



II

AB Title compds. Q-L1-P-L2-M-X-L3-A [Q = H, (hetero)aryl, alkyl, etc.; L1 = bond, alkylene, heteroalkylene, O, etc.; P = (hetero)arom., cycloalkylene, etc.; L2 = bond, alkylene, heteroalkylene, etc.; M = (hetero)arom., cycloalkylene, arylalkylene, etc.; X = divalent alkyl, (un)substituted-N; O, SO0-2; L3 = bond, alkylene, heteroalkylene, etc.; A = COOH, tetrazolyl, SO3H, PO3H2, etc.; I] are prepd. For instance, (S)-3-[4-((4'- trifluoromethyl-1,1'-biphenyl-3-yl)methoxy)phenyl]hexan-4-ynoic acid (II) is prepd. in 5 steps from (S)-3-(4-hydroxyphenyl)hexan-4-ynoic acid Me ester (prepn. given), 4-(trifluoromethyl)phenylboronic acid and 3-bromobenzoic acid. II has an EC50 < 0.1 .mu.M for human G protein-coupled receptor GPR40. I are useful for the treatment of type II diabetes.

L11 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
GI



I



II

AB Title pyrazoles, imidazoles, and (is)oxazoles I [wherein R1 = H, (un)substituted alkyl, alkenyl, (hetero)aryl(alkyl), arylheteroalkyl, cycloalkylaryl(alkyl); R2 = absent, (hetero)alkyl; R8 = H, alkyl, alkylenyl, halo; R9 = H, (un)substituted alkyl, alkylenyl, halo, aryl(alkyl), heteroaryl, allyl, alkoxy, alkylthio, etc.; R10, R11 = independently H, OH, CN, NO2, halo, oxo, (un)substituted (halo)alkyl, alkoxy, cycloalkyl, (hetero)aryl(alkyl), cycloalkylaryl(alkyl), aryloxy, acyl, carboxy, amino, sulfamoyl, etc.; R32 = bond, H, halo, (halo)alkyl, alkyloxo; E = (un)substituted carboxy(methyl), tetrazolyl(methyl), nitriloalkyl, carboxamido(methyl), sulfonamido(methyl); U = (un)substituted aliph. linker wherein one C of the linker is optionally replaced with O, NH, or S; X = bond, O, S, SO2, NH; Y = bond, CH2, NH; Z1, Z2 = independently N, O, C, whit the proviso that at least one of Z1 and Z2 = N; Z3 = N, O, C; or stereoisomers, pharmaceutically acceptable salts, solvates, and hydrates thereof] were prepd. as peroxisome proliferator activated receptor (PPAR) modulators (no data). For example, chlorination of [3-methyl-1-(4-trifluoromethylphenyl)-1H-pyrazol-4-yl]methanol with MeSO2Cl and TEA in CH2Cl2, followed by coupling with (4-hydroxy-2- methylphenoxy)acetic acid Me ester using Cs2CO3 in acetonitrile and sapon. with NaOH in MeOH provided II. I and their pharmaceutical compns. are expected to be effective in treating and preventing metabolic disorders, diabetes mellitus, atherosclerosis, and cardiovascular disorders (no data).

L11 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
GI



I



II

AB Title compds. I [wherein R1 = H, CF3, (un)substituted alkyl, cycloalkyl, heterocyclyl, etc.; R2 = (un)substituted alkyl, amino, COH, etc.; n = 0-6; R11 and R12 = independently H, alkyl, CO2H and derivs., OH and derivs., NH2 and derivs., etc.; their analogs, derivs., solvates or salts] were prepd. for modulating peroxisome proliferator activated receptors (PPARs), in particular as PPAR.gamma. agonists, and for treating and/or preventing various diseases and conditions mediated by said nuclear receptors, including metabolic or cell proliferative disorders (no data). For example, 1-phenyl-3-(thiophen-2-yl)-1H-pyrazole-4-carboxaldehyde (prepn. given) was reacted with 1-(4-methoxyphenyl)ethanone in isopropanol to give II in 67% yield. II inhibited adipocyte differentiation induced by rosiglitazone by about 68%, demonstrating its antagonistic activity towards human PPAR.gamma.. II induced adipocyte differentiation (25% of rosiglitazone efficacy), proving its human PPAR.gamma. partial agonistic activity. I are useful for treating diabetes, atherosclerosis, hyperglycemia, dyslipidemia, obesity, syndrome X, insulin resistance, hypertension, neuropathy, microvascular diseases (e.g. retinopathy, nephropathy), macrovascular diseases (e.g. myocardial infarction, stroke, heart failure) in mammals.(no data).

=> d ibib abs tot

L11 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2005:1026833 CAPLUS Full-text
DOCUMENT NUMBER:	143:326090
TITLE:	Preparation of arylmethoxyphenyl-alkylcarboxylic acids and related derivatives for use in treating metabolic disorders
INVENTOR(S):	Akerman, Michelle; Houze, Jonathan; Lin, Daniel C. H.; Liu, Jiwen; Luo, Jian; Medina, Julio C.; Qiu, Wei; Reagan, Jeffrey D.; Sharma, Rajiv; Shuttleworth, Stephen J.; Sun, Ying; Zhang, Jian; Zhu, Liusheng
PATENT ASSIGNEE(S):	Amgen Inc., USA; et al.
SOURCE:	PCT Int. Appl., 163 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005086661	A2	20050922	WO 2005-US5815	20050224
WO 2005086661	A3	20060504		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005220728	A2	20050922	AU 2005-220728	20050224
AU 2005220728	A1	20050922		
CA 2558585	A1	20050922	CA 2005-2558585	20050224
EP 1737809	A2	20070103	EP 2005-723623	20050224
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1946666	A	20070411	CN 2005-80012709	20050224
US 2006004012	A1	20060105	US 2005-67377	20050225
MX 2006PA09793	A	20061030	MX 2006-PA9793	20060828
US 2007142384	A1	20070621	US 2006-591214	20060828
NO 2006004362	A	20061122	NO 2006-4362	20060926
PRIORITY APPLN. INFO.:			US 2004-548741P P	20040227
			US 2004-601579P P	20040812
			WO 2005-US5815 W	20050224

OTHER SOURCE(S): MARPAT 143:326090

GI



II

AB Title compds. Q-L1-P-L2-M-X-L3-A [Q = H, (hetero)aryl, alkyl, etc.; L1 = bond, alkylene, heteroalkylene, O, etc.; P = (hetero)arom., cycloalkylene, etc.; L2 = bond, alkylene, heteroalkylene, etc.; M = (hetero)arom., cycloalkylene, arylalkylene, etc.; X = divalent alkyl, (un)substituted-N; O, SO0-2; L3 = bond, alkylene, heteroalkylene, etc.; A = COOH, tetrazolyl, SO3H, PO3H2, etc.; I] are prepd. For instance, (S)-3-[4-((4'- trifluoromethyl-1,1'-biphenyl-3-yl)methoxy)phenyl]hexan-4-ynoic acid (II) is prepd. in 5 steps from (S)-3-(4-hydroxyphenyl)hexan-4-ynoic acid Me ester (prepn. given), 4-(trifluoromethyl)phenylboronic acid and 3-bromobenzoic acid. II has an EC50 < 0.1 .mu.M for human G protein-coupled receptor GPR40. I are useful for the treatment of type II diabetes.

L11 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:606448 CAPLUS Full-text
DOCUMENT NUMBER: 141:157111
TITLE: Preparation of pyrazoles and analogs as PPAR modulators for treatment of metabolic disorders, diabetes mellitus, atherosclerosis, and cardiovascular disorders
INVENTOR(S): Conner, Scott Eugene; Ma, Tianwei; Mantlo, Nathan Bryan; Mayhugh, Daniel Ray; Schkeryantz, Jeffrey Michael; Warshawsky, Alan M.; Zhu, Guoxin
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 214 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004063166	A1	20040729	WO 2003-US39119	20031231
WO 2004063166	A8	20050303		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003296404	A1	20040810	AU 2003-296404	20031231
EP 1585733	A1	20051019	EP 2003-815195	20031231
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, BG, CZ, EE, HU, SK				
US 2006241157	A1	20061026	US 2005-540341	20050621
PRIORITY APPLN. INFO.:			US 2003-438563P P	20030106
			WO 2003-US39119 W	20031231

OTHER SOURCE(S): MARPAT 141:157111
GI



I



II

AB Title pyrazoles, imidazoles, and (is)oxazoles I [wherein R1 = H, (un)substituted alkyl, alkenyl, (hetero)aryl(alkyl), arylheteroalkyl, cycloalkylaryl(alkyl); R2 = absent, (hetero)alkyl; R8 = H, alkyl, alkylenyl, halo; R9 = H, (un)substituted alkyl, alkylenyl, halo, aryl(alkyl), heteroaryl, allyl, alkoxy, alkylthio, etc.; R10, R11 = independently H, OH, CN, NO2, halo, oxo, (un)substituted (halo)alkyl, alkoxy, cycloalkyl, (hetero)aryl(alkyl), cycloalkylaryl(alkyl), aryloxy, acyl, carboxy, amino, sulfamoyl, etc.; R32 = bond, H, halo, (halo)alkyl, alkyloxo; E = (un)substituted carboxy(methyl), tetrazolyl(methyl), nitriloalkyl, carboxamido(methyl), sulfonamido(methyl); U = (un)substituted aliph. linker wherein one C of the linker is optionally replaced with O, NH, or S; X = bond, O, S, SO2, NH; Y = bond, CH2, NH; Z1, Z2 = independently N, O, C, whit the proviso that at least one of Z1 and Z2 = N; Z3 = N, O, C; or stereoisomers, pharmaceutically acceptable salts, solvates, and hydrates thereof] were prepd. as peroxisome proliferator activated receptor (PPAR) modulators (no data). For example, chlorination of [3-methyl-1-(4-trifluoromethylphenyl)-1H-pyrazol-4-yl]methanol with MeSO2Cl and TEA in CH2Cl2, followed by coupling with (4-hydroxy-2- methylphenoxy)acetic acid Me ester using Cs2CO3 in acetonitrile and sapon. with NaOH in MeOH provided II. I and their pharmaceutical compns. are expected to be effective in treating and preventing metabolic disorders, diabetes mellitus, atherosclerosis, and cardiovascular disorders (no data).

L11 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2004:430797 CAPLUS Full-text
DOCUMENT NUMBER:	141:7108
TITLE:	Preparation of pyrazoles as modulators of peroxisome proliferator activated receptors (PPARs), in particular PPAR.gamma. agonists
INVENTOR(S):	Huck, Jacques; Saladin, Regis; Sierra, Michael
PATENT ASSIGNEE(S):	Carex SA, Fr.
SOURCE:	PCT Int. Appl., 156 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043951	A1	20040527	WO 2003-EP311855	20031024

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003282051	A1	20040603	AU 2003-282051		20031024
PRIORITY APPLN. INFO.:			EP 2002-360298	A	20021024
			EP 2002-360372	A	20021220
			EP 2002-360373	A	20021220
			US 2003-456954P	P	20030325
			EP 2003-360070	A	20030611
			EP 2003-360091	A	20030724
			WO 2003-EP11855	W	20031024

OTHER SOURCE(S): MARPAT 141:7108

GI



I



II

AB Title compds. I [wherein R1 = H, CF3, (un)substituted alkyl, cycloalkyl, heterocyclyl, etc.; R2 = (un)substituted alkyl, amino, COH, etc.; n = 0-6; R11 and R12 = independently H, alkyl, CO2H and derivs., OH and derivs., NH2 and derivs., etc.; their analogs, derivs., solvates or salts] were prepd. for modulating peroxisome proliferator activated receptors (PPARs), in particular as PPAR.gamma. agonists, and for treating and/or preventing various diseases and conditions mediated by said nuclear receptors, including metabolic or cell proliferative disorders (no data). For example, 1-phenyl-3-(thiophen-2-yl)-1H-pyrazole-4-carboxaldehyde (prepn. given) was reacted with 1-(4-methoxyphenyl)ethanone in isopropanol to give II in 67% yield. II inhibited adipocyte differentiation induced by rosiglitazone by about 68%, demonstrating its antagonistic activity towards human PPAR.gamma.. II induced adipocyte differentiation (25% of rosiglitazone efficacy), proving its human PPAR.gamma. partial agonistic activity. I are useful for treating diabetes, atherosclerosis, hyperglycemia, dyslipidemia, obesity, syndrome X, insulin resistance, hypertension, neuropathy, microvascular diseases (e.g. retinopathy, nephropathy), macrovascular diseases (e.g. myocardial infarction, stroke, heart failure) in mammals.(no data).

=> d l9 ibib abs tot

L9 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1026833 CAPLUS Full-text
DOCUMENT NUMBER: 143:326090
TITLE: Preparation of arylmethoxyphenyl-alkylcarboxylic acids and related derivatives for use in treating metabolic disorders
INVENTOR(S): Akerman, Michelle; Houze, Jonathan; Lin, Daniel C. H.; Liu, Jiwen; Luo, Jian; Medina, Julio C.; Qiu, Wei; Reagan, Jeffrey D.; Sharma, Rajiv; Shuttleworth, Stephen J.; Sun, Ying; Zhang, Jian; Zhu, Liusheng
PATENT ASSIGNEE(S): Amgen Inc., USA; et al.
SOURCE: PCT Int. Appl., 163 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005086661	A2	20050922	WO 2005-US5815		20050224
WO 2005086661	A3	20060504			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2005220728	A2	20050922	AU 2005-220728		20050224
AU 2005220728	A1	20050922			
CA 2558585	A1	20050922	CA 2005-2558585		20050224
EP 1737809	A2	20070103	EP 2005-723623		20050224
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU					
CN 1946666	A	20070411	CN 2005-80012709		20050224
US 2006004012	A1	20060105	US 2005-67377		20050225
MX 2006PA09793	A	20061030	MX 2006-PA9793		20060828
US 2007142384	A1	20070621	US 2006-591214		20060828
NO 2006004362	A	20061122	NO 2006-4362		20060926
PRIORITY APPLN. INFO.:			US 2004-548741P	P	20040227
			US 2004-601579P	P	20040812
			WO 2005-US5815	W	20050224

OTHER SOURCE(S): MARPAT 143:326090
GI



II

AB Title compds. Q-L1-P-L2-M-X-L3-A [Q = H, (hetero)aryl, alkyl, etc.; L1 = bond, alkylene, heteroalkylene, O, etc.; P = (hetero)arom., cycloalkylene, etc.; L2 = bond, alkylene, heteroalkylene, etc.; M = (hetero)arom., cycloalkylene, arylalkylene, etc.; X = divalent alkyl, (un)substituted-N; O, SO0-2; L3 = bond, alkylene, heteroalkylene, etc.; A = COOH, tetrazolyl, SO3H, PO3H2, etc.; I] are prepd. For instance, (S)-3-[4-((4'- trifluoromethyl-1,1'-biphenyl-3-yl)methoxy)phenyl]hexan-4-ynoic acid (II) is prepd. in 5 steps from (S)-3-(4-hydroxyphenyl)hexan-4-ynoic acid Me ester (prepn. given), 4-(trifluoromethyl)phenylboronic acid and 3-bromobenzoic acid. II has an EC50 < 0.1 .mu.M for human G protein-coupled receptor GPR40. I are useful for the treatment of type II diabetes.

L9 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:995925 CAPLUS Full-text
DOCUMENT NUMBER: 141:424182
TITLE: Preparation of pyrazole-amine compounds useful as kinase inhibitors
INVENTOR(S): Dyckman, Alaric; Das, Jagabandhu; Leftheris, Katerina; Liu, Chunjian; Moquin, Robert V.; Wrobleski, Stephen T.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004098528	A2	20041118	WO 2004-US13786	20040503
WO 2004098528	A3	20050714		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004248853	A1	20041209	US 2004-838006	20040503
US 7151113	B2	20061219		
US 2005004176	A1	20050106	US 2004-837778	20040503

US 2005159424	A1	20050721	US 2004-838129	20040503
EP 1620108	A2	20060201	EP 2004-760705	20040503
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
US 2006247247	A1	20061102	US 2006-477010	20060628
PRIORITY APPLN. INFO.:			US 2003-467029P	P 20030501
			US 2004-838006	A3 20040503
			WO 2004-US13786	W 20040503

OTHER SOURCE(S): MARPAT 141:424182

GI



I



II

AB The title compds. I [G = Ph, pyridyl; W = CH2O, CO2, NHCHR8, CHR8NH, NHCO(CHR8)r (wherein R8 = H, alkyl; r = 0-2); R1 = H, (un)substituted alkyl, aryl, etc.; R2 = H, (un)substituted alkyl, alkoxy, etc.; R3 = H, CF3, OCF3, etc.; R4 = H, (un)substituted alkyl, halo, etc.; R5 = CF3, OCF3, CN, etc.; X = CONH, NHCO, NHCO2, SO2NH, CO2, or is absent; R6 = H, (un)substituted alkyl, alkoxy, etc.; m = 0-3], useful for treating p38 kinase-assocd. conditions (such as inflammatory disorder)in a mammal (no data), were prepd. E.g., a 3-step synthesis of II, starting from 1-phenyl-5-propyl-1H-pyrazole-4-carbonyl chloride, was given.

L9 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2004:606448 CAPLUS Full-text
DOCUMENT NUMBER:	141:157111
TITLE:	Preparation of pyrazoles and analogs as PPAR modulators for treatment of metabolic disorders, diabetes mellitus, atherosclerosis, and cardiovascular disorders
INVENTOR(S):	Conner, Scott Eugene; Ma, Tianwei; Mantlo, Nathan Bryan; Mayhugh, Daniel Ray; Schkeryantz, Jeffrey Michael; Warshawsky, Alan M.; Zhu, Guoxin
PATENT ASSIGNEE(S):	Eli Lilly and Company, USA
SOURCE:	PCT Int. Appl., 214 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	2
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004063166	A1	20040729	WO 2003-US39119	20031231
WO 2004063166	A8	20050303		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003296404	A1	20040810	AU 2003-296404		20031231
EP 1585733	A1	20051019	EP 2003-815195		20031231
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, BG, CZ, EE, HU, SK					
US 2006241157	A1	20061026	US 2005-540341		20050621
PRIORITY APPLN. INFO.:			US 2003-438563P	P	20030106
			WO 2003-US39119	W	20031231

OTHER SOURCE(S): MARPAT 141:157111

GI



I



II

AB Title pyrazoles, imidazoles, and (is)oxazoles I [wherein R1 = H, (un)substituted alkyl, alkenyl, (hetero)aryl(alkyl), arylheteroalkyl, cycloalkylaryl(alkyl); R2 = absent, (hetero)alkyl; R8 = H, alkyl, alkylenyl, halo; R9 = H, (un)substituted alkyl, alkylenyl, halo, aryl(alkyl), heteroaryl, allyl, alkoxy, alkylthio, etc.; R10, R11 = independently H, OH, CN, NO2, halo, oxo, (un)substituted (halo)alkyl, alkoxy, cycloalkyl, (hetero)aryl(alkyl), cycloalkylaryl(alkyl), aryloxy, acyl, carboxy, amino, sulfamoyl, etc.; R32 = bond, H, halo, (halo)alkyl, alkyloxo; E = (un)substituted carboxy(methyl), tetrazolyl(methyl), nitriloalkyl, carboxamido(methyl), sulfonamido(methyl); U = (un)substituted aliph. linker wherein one C of the linker is optionally replaced with O, NH, or S; X = bond, O, S, SO2, NH; Y = bond, CH2, NH; Z1, Z2 = independently N, O, C, whit the proviso that at least one of Z1 and Z2 = N; Z3 = N, O, C; or stereoisomers, pharmaceutically acceptable salts, solvates, and hydrates thereof] were prepd. as peroxisome proliferator activated receptor (PPAR) modulators (no data). For example, chlorination of [3-methyl-1-(4-trifluoromethylphenyl)-1H-pyrazol-4-yl]methanol with MeSO2Cl and TEA in CH2Cl2, followed by coupling with (4-hydroxy-2- methylphenoxy)acetic acid Me ester using Cs2CO3 in acetonitrile and sapon. with NaOH in MeOH provided II. I and their pharmaceutical compns. are expected to be effective in treating and preventing metabolic disorders, diabetes mellitus, atherosclerosis, and cardiovascular disorders (no data).

L9 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:430797 CAPLUS Full-text
DOCUMENT NUMBER: 141:7108
TITLE: Preparation of pyrazoles as modulators of peroxisome proliferator activated receptors (PPARs), in particular PPAR.gamma. agonists
INVENTOR(S): Huck, Jacques; Saladin, Regis; Sierra, Michael
PATENT ASSIGNEE(S): Carex SA, Fr.
SOURCE: PCT Int. Appl., 156 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043951	A1	20040527	WO 2003-EP311855	20031024
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003282051	A1	20040603	AU 2003-282051	20031024

PRIORITY APPLN. INFO.:

EP 2002-360298	A	20021024
EP 2002-360372	A	20021220
EP 2002-360373	A	20021220
US 2003-456954P	P	20030325
EP 2003-360070	A	20030611
EP 2003-360091	A	20030724
WO 2003-EP11855	W	20031024

OTHER SOURCE(S): MARPAT 141:7108
GI



I



II

AB Title compds. I [wherein R1 = H, CF3, (un)substituted alkyl, cycloalkyl, heterocyclyl, etc.; R2 = (un)substituted alkyl, amino, COH, etc.; n = 0-6; R11 and R12 = independently H, alkyl, CO2H and derivs., OH and derivs., NH2 and derivs., etc.; their analogs, derivs., solvates or salts] were prepd. for modulating peroxisome proliferator activated receptors (PPARs), in particular as PPAR.gamma. agonists, and for treating and/or preventing various diseases and conditions mediated by said nuclear receptors, including metabolic or cell proliferative disorders (no data). For example, 1-phenyl-3-(thiophen-2-yl)-1H-pyrazole-4-carboxaldehyde (prepn. given) was reacted with 1-(4-methoxyphenyl)ethanone in isopropanol to give II in 67% yield. II inhibited adipocyte differentiation induced by rosiglitazone by about 68%, demonstrating its antagonistic activity towards human PPAR.gamma.. II induced adipocyte differentiation (25% of rosiglitazone efficacy), proving its human PPAR.gamma. partial agonistic activity. I are useful for treating diabetes, atherosclerosis, hyperglycemia, dyslipidemia, obesity, syndrome X, insulin resistance, hypertension, neuropathy, microvascular diseases (e.g. retinopathy, nephropathy), macrovascular diseases (e.g. myocardial infarction, stroke, heart failure) in mammals.(no data).

L9 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:220534 CAPLUS Full-text
DOCUMENT NUMBER: 136:263165
TITLE: Preparation of 1,2,3,4-tetrahydronaphthalenecarboxamide, 1,2,3,4-tetrahydroquinolinecarboxamide, indanecarboxamides, thiochromancarboxamide, and chromancarboxamide derivatives as C5a receptor antagonists and medicinal use thereof
INVENTOR(S): Nakamura, Mitsuharu; Kamahori, Takao; Ishibuchi, Seigo; Naka, Yoichi; Sumichika, Hiroshi; Itoh, Katsuhiko
PATENT ASSIGNEE(S): Mitsubishi Pharma Corporation, Japan
SOURCE: PCT Int. Appl., 415 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022556	A1	20020321	WO 2001-JP7977	20010914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001088045	A5	20020326	AU 2001-88045	20010914
CA 2422342	A1	20030313	CA 2001-2422342	20010914
EP 1318140	A1	20030611	EP 2001-967682	20010914
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004138223	A1	20040715	US 2003-380502	20030508
PRIORITY APPLN. INFO.:			JP 2000-280540	A 20000914

JP 2000-386813 A 20001220
WO 2001-JP7977 W 20010914

OTHER SOURCE(S): MARPAT 136:263165
GI



I

AB Amide derivs. represented by the following general formula [I; R1, R2, R3, R4 = H, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, or alkoxy, aryloxy, arylalkyloxy, (un)substituted acyloxy, halo, NO2, cyano, acyl SH, alkylthio, alkylsulfinyl, NH2, alkylamino, dialkylamino, cyclic amino, (un)substituted CONH2, alkoxycarbonyl, CO2h, acylamino, (un)substituted SO2NH2, haloalkyl; or any two of R1, R2, and R3 together with adjacent carbon atom form a ring; all a, b, c, d, and e is a carbon atom; or one or two of a, b, c, d, and e represent one or two nitrogen atom and the other represent C atoms; R4, R5, R6 = haloalkyloxy, groups listed in R1 - R4; A = H, (un)substituted cycloalkyl, aryl, heteroaryl, or cyclic amino; W1, W2 = a bond, (un)substituted C1-3 alkylene; Y = a single bond, O, CO, NR7, S, SO, SO2, CONR8, NR9CO (wherein R7, R8, R9 = H, (un)substituted alkyl); Z = a single bond, (un)substituted alkylene] or optically active isomers thereof or pharmaceutically acceptable salts thereof are prepd. These compds. are useful as preventives and remedies for diseases or syndromes caused by inflammation induced by C5a, e.g. immunol. diseases such as rheumatism and systemic lupus erythematosus, allergic diseases such as sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease and asthma, atherosclerosis, heart infarction, brain infarction, psoriasis, Alzheimer's disease and important organistic breakdown (e.g. pneumonia, nephritis, hepatitis, pancreatitis) induced by leukocyte activation caused by ischemic reperfusion, burn or surgical invasion. Moreover, they are useful as preventives and remedies for infection with bacteria and viruses mediated by C5a receptor. Thus, to a soln. of 3.3 g 1,2,3,4-tetrahydronaphthalene-1-carboxylic acid in 20 mL CH2Cl2 was added 2.1 mL SO2Cl2 and the resulting mixt. was refluxed for 3 h, concd. under reduced pressure, dissolved in 10 mL CH2Cl2, treated with a soln. of 5.1 g N-[(4-dimethylaminophenyl)methyl](4-isopropylphenyl)amine in 10 mL CH2Cl2 under ice-cooling, warmed to room temp., and stirred overnight to give N-[(4-dimethylaminophenyl)methyl]-N-(4-isopropylphenyl)- 1,2,3,4-tetrahydronaphthalene-1-carboxamide (II). II inhibited the binding of [125I]-human C5a receptor to human histiocystic lymphoma cell line (U-937) with IC50 of 104 nm/mL. A tablet, a capsule, an injection soln., and an eyedrop formulation contg. II were prepd.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:142660 CAPLUS Full-text
DOCUMENT NUMBER: 136:200179
TITLE: Preparation of N,N'-diarylurea derivatives as complement receptor C5a antagonists
INVENTOR(S): Ishibuchi, Seigo; Sumichika, Hiroshi; Itoh, Katsuhiko;

	Naka, Yoichi
PATENT ASSIGNEE(S):	Welfide Corporation, Japan
SOURCE:	PCT Int. Appl., 90 pp.
	CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	Japanese
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002014265	A1	20020221	WO 2001-JP6902	20010810
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2418652	A1	20020221	CA 2001-2418652	20010810
AU 2001077751	A5	20020225	AU 2001-77751	20010810
EP 1308438	A1	20030507	EP 2001-955657	20010810
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003207939	A1	20031106	US 2003-343961	20030205
US 7105567	B2	20060912		

PRIORITY APPLN. INFO.:		JP 2000-243290	A 20000810
		WO 2001-JP6902	W 20010810
OTHER SOURCE(S):	MARPAT 136:200179		

GI



I

AB N,N'-diarylurea derivs. represented by the following general formula [I; R1, R2, R3 = H, (un)substituted alkyl, cycloalkyl, alkenyl, or alkynyl, HO, (un)substituted alkoxy, SH, (un)substituted alkylthio, halo, NO2, cyano, amino, alkylamino, cyclic amino, alkylsulfonyl, CONH2, acylamino, sulfamoyl, acyl, CO2H, alkoxycarbonyl, (un)substituted aryl or heteroaryl; D = a bond, (un)substituted alkylene; A = (un)substituted alkyl, cycloalkyl, aryl, or heteroaryl; R4, R5 = H, (un)substituted alkyl or alkoxy, HO, halo; R6 = H, (un)substituted alkyl or alkoxy, HO, halo; X = O, S] or pharmaceutically acceptable salts thereof are prepd. Because of having a C5a receptor antagonism, these compds. are useful as remedies and preventives for diseases or syndromes induced by C5a, e.g. autoimmune diseases such as rheumatism and systemic lupus erythematosus, allergic diseases such as sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease and asthma, atherosclerosis, cardiac infarction, brain infarction, psoriasis,

Alzheimer's disease and serious organ injuries by the activation of leukocytes caused by ischemia, trauma, burn, surgical invasion, etc. (for example, pneumonia, nephritis, hepatitis and pancreatitis). Moreover, these compds. are also useful as remedies and preventives for bacterial and viral infections mediated by C5a receptor. Thus, to a soln. of (4-isopropylphenyl)[[1-(4-trifluoromethylbenzyl)pyrazol-4-yl]methyl]amine in toluene was added 2,6-diisopropylphenyl isocyanate and stirred at room temp. overnight to give N'-(2,6-diisopropylphenyl)-N-(4-isopropylphenyl)-N-[[1-(4-trifluoromethylbenzyl)pyrazol-4-yl]methyl]urea. N'-(2,6- diisopropylphenyl)-N-[(4-dimethylaminophenyl)methyl]-N-(4- isopropylphenyl)urea 9/10 fumarate showed IC50 of 5 nmol/L for inhibiting the Ca2+ ion increase in C5a-simulated blood neutrophil. Pharmaceutical formulations, e.g. a capsule contg. N'-(2,6-diisopropylphenyl)-N-[(4- dimethylaminophenyl)methyl]-N-(4-fluorophenyl)urea.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l8 ibib abs tot

L8 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1026833 CAPLUS Full-text

DOCUMENT NUMBER: 143:326090

TITLE: Preparation of arylmethoxyphenyl-alkylcarboxylic acids and related derivatives for use in treating metabolic disorders

INVENTOR(S): Akerman, Michelle; Houze, Jonathan; Lin, Daniel C. H.; Liu, Jiwen; Luo, Jian; Medina, Julio C.; Qiu, Wei; Reagan, Jeffrey D.; Sharma, Rajiv; Shuttleworth, Stephen J.; Sun, Ying; Zhang, Jian; Zhu, Liusheng

PATENT ASSIGNEE(S): Amgen Inc., USA; et al.

SOURCE: PCT Int. Appl., 163 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005086661	A2	20050922	WO 2005-US5815	20050224
WO 2005086661	A3	20060504		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005220728	A2	20050922	AU 2005-220728	20050224
AU 2005220728	A1	20050922		
CA 2558585	A1	20050922	CA 2005-2558585	20050224
EP 1737809	A2	20070103	EP 2005-723623	20050224
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1946666	A	20070411	CN 2005-80012709	20050224

US 2006004012	A1	20060105	US 2005-67377		20050225
MX 2006PA09793	A	20061030	MX 2006-PA9793		20060828
US 2007142384	A1	20070621	US 2006-591214		20060828
NO 2006004362	A	20061122	NO 2006-4362		20060926
PRIORITY APPLN. INFO.:			US 2004-548741P	P	20040227
			US 2004-601579P	P	20040812
			WO 2005-US5815	W	20050224

OTHER SOURCE(S): MARPAT 143:326090

GI



II

AB Title compds. Q-L1-P-L2-M-X-L3-A [Q = H, (hetero)aryl, alkyl, etc.; L1 = bond, alkylene, heteroalkylene, O, etc.; P = (hetero)arom., cycloalkylene, etc.; L2 = bond, alkylene, heteroalkylene, etc.; M = (hetero)arom., cycloalkylene; arylalkylene, etc.; X = divalent alkyl, (un)substituted-N; O, SO0-2; L3 = bond, alkylene, heteroalkylene, etc.; A = COOH, tetrazolyl, SO3H, PO3H2, etc.; I] are prepd. For instance, (S)-3-[4-((4'- trifluoromethyl-1,1'-biphenyl-3-yl)methoxy)phenyl]hexan-4-ynoic acid (II) is prepd. in 5 steps from (S)-3-(4-hydroxyphenyl)hexan-4-ynoic acid Me ester (prepn. given), 4-(trifluoromethyl)phenylboronic acid and 3-bromobenzoic acid. II has an EC50 < 0.1 .mu.M for human G protein-coupled receptor GPR40. I are useful for the treatment of type II diabetes.

L8 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2005:395278 CAPLUS Full-text
DOCUMENT NUMBER:	142:447209
TITLE:	Preparation of .alpha.-hydroxyimino-.beta.-benzylpropanoate derivatives as PPAR.gamma. and PPAR.alpha. agonists for the treatment of diabetes mellitus and inflammation diseases
INVENTOR(S):	Kim, Geun Tae; Koh, Jong Sung; Han, Hee Oon; Kim, Seung Hae; Kim, Kyoung-Hee; Chung, Hee-Kyung; Kim, Yeon Chul; Kim, Misun; Koo, Ki Dong; Yim, Hyeon Joo; Hur, Gwong-Cheung; Lee, Sun Hwa; Lee, Chang-Seok; Woo, Sung Ho
PATENT ASSIGNEE(S):	LG Life Sciences Ltd., S. Korea
SOURCE:	PCT Int. Appl., 211 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005040127	A1	20050506	WO 2004-KR2729	20041027

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

KR 2005040746	A	20050503	KR 2004-86055		20041027
PRIORITY APPLN. INFO.:			KR 2003-75037	A	20031027
			KR 2003-75041	A	20031027
			KR 2003-75046	A	20031027

OTHER SOURCE(S): MARPAT 142:447209
GI



I



II

AB Title compds. I [wherein A = (un)substituted (cyclo)alkyl, (hetero)aryl, amine, amido, alkoxy, sulfonyl or sulfanyl; B, D, X = H or alkyl; E = H, alkyl or aryl; and pharmaceutically acceptable nontoxic salts, physiol. hydrolyzable esters, hydrates, solvates, isomers or prodrugs thereof] were prepd. as agonists of peroxisome proliferator-activated receptor gamma (PPAR.gamma.) and alpha (PPAR.alpha.). For example, II was synthesized via etherification of the corresponding phenol (prepn. given) with methanesulfonate ester of the pyrazolemethanol (prepn. given) in 40% yield. I were found to be very effective for accelerating the activity of PPAR.gamma. and PPARa with EC50 values of <1 .mu.M and <1000 nM (<100 nM for II), resp. Therefore, I are useful for treating or preventing PPAR.gamma.- and PPARa-related diseases, such as diabetes mellitus, its complications and inflammation.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:995925 CAPLUS Full-text
DOCUMENT NUMBER: 141:424182
TITLE: Preparation of pyrazole-amine compounds useful as kinase inhibitors

INVENTOR(S): Dyckman, Alaric; Das, Jagabandhu; Leftheris, Katerina; Liu, Chunjian; Moquin, Robert V.; Wrobleski, Stephen T.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004098528	A2	20041118	WO 2004-US13786	20040503
WO 2004098528	A3	20050714		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004248853	A1	20041209	US 2004-838006	20040503
US 7151113	B2	20061219		
US 2005004176	A1	20050106	US 2004-837778	20040503
US 2005159424	A1	20050721	US 2004-838129	20040503
EP 1620108	A2	20060201	EP 2004-760705	20040503
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
US 2006247247	A1	20061102	US 2006-477010	20060628

PRIORITY APPLN. INFO.:

US 2003-467029P	P	20030501
US 2004-838006	A3	20040503
WO 2004-US13786	W	20040503

OTHER SOURCE(S): MARPAT 141:424182

GI



I



II

AB The title compds. I [G = Ph, pyridyl; W = CH2O, CO2, NHCHR8, CHR8NH, NHCO(CHR8)r (wherein R8 = H, alkyl; r = 0-2); R1 = H, (un)substituted alkyl, aryl, etc.; R2 = H, (un)substituted alkyl, alkoxy, etc.; R3 = H, CF3, OCF3, etc.; R4 = H, (un)substituted alkyl, halo, etc.; R5 = CF3, OCF3, CN, etc.; X = CONH, NHCO, NHCO2, SO2NH, CO2, or is absent; R6 = H, (un)substituted alkyl, alkoxy, etc.; m = 0-3], useful for treating p38 kinase-assocd. conditions

(such as inflammatory disorder)in a mammal (no data), were prepd. E.g., a 3-step synthesis of II, starting from 1-phenyl-5-propyl-1H-pyrazole-4-carbonyl chloride, was given.

L8 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:606448 CAPLUS Full-text
DOCUMENT NUMBER: 141:157111
TITLE: Preparation of pyrazoles and analogs as PPAR modulators for treatment of metabolic disorders, diabetes mellitus, atherosclerosis, and cardiovascular disorders
INVENTOR(S): Conner, Scott Eugene; Ma, Tianwei; Mantlo, Nathan Bryan; Mayhugh, Daniel Ray; Schkeryantz, Jeffrey Michael; Warshawsky, Alan M.; Zhu, Guoxin
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 214 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004063166	A1	20040729	WO 2003-US39119	20031231
WO 2004063166	A8	20050303		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003296404	A1	20040810	AU 2003-296404	20031231
EP 1585733	A1	20051019	EP 2003-815195	20031231
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, BG, CZ, EE, HU, SK				
US 2006241157	A1	20061026	US 2005-540341	20050621
PRIORITY APPLN. INFO.:			US 2003-438563P	P 20030106
			WO 2003-US39119	W 20031231

OTHER SOURCE(S): MARPAT 141:157111
GI



I



II

AB Title pyrazoles, imidazoles, and (is)oxazoles I [wherein R1 = H, (un)substituted alkyl, alkenyl, (hetero)aryl(alkyl), arylheteroalkyl, cycloalkylaryl(alkyl); R2 = absent, (hetero)alkyl; R8 = H, alkyl, alkylenyl, halo; R9 = H, (un)substituted alkyl, alkylenyl, halo, aryl(alkyl), heteroaryl, allyl, alkoxy, alkylthio, etc.; R10, R11 = independently H, OH, CN, NO2, halo, oxo, (un)substituted (halo)alkyl, alkoxy, cycloalkyl, (hetero)aryl(alkyl), cycloalkylaryl(alkyl), aryloxy, acyl, carboxy, amino, sulfamoyl, etc.; R32 = bond, H, halo, (halo)alkyl, alkyloxo; E = (un)substituted carboxy(methyl), tetrazolyl(methyl), nitriloalkyl, carboxamido(methyl), sulfonamido(methyl); U = (un)substituted aliph. linker wherein one C of the linker is optionally replaced with O, NH, or S; X = bond, O, S, SO2, NH; Y = bond, CH2, NH; Z1, Z2 = independently N, O, C, whit the proviso that at least one of Z1 and Z2 = N; Z3 = N, O, C; or stereoisomers, pharmaceutically acceptable salts, solvates, and hydrates thereof] were prepd. as peroxisome proliferator activated receptor (PPAR) modulators (no data). For example, chlorination of [3-methyl-1-(4-trifluoromethylphenyl)-1H-pyrazol-4-yl]methanol with MeSO2Cl and TEA in CH2Cl2, followed by coupling with (4-hydroxy-2- methylphenoxy)acetic acid Me ester using Cs2CO3 in acetonitrile and sapon. with NaOH in MeOH provided II. I and their pharmaceutical compns. are expected to be effective in treating and preventing metabolic disorders, diabetes mellitus, atherosclerosis, and cardiovascular disorders (no data).

L8 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:430797 CAPLUS Full-text
DOCUMENT NUMBER: 141:7108
TITLE: Preparation of pyrazoles as modulators of peroxisome proliferator activated receptors (PPARs), in particular PPAR.gamma. agonists
INVENTOR(S): Huck, Jacques; Saladin, Regis; Sierra, Michael
PATENT ASSIGNEE(S): Carex SA, Fr.
SOURCE: PCT Int. Appl., 156 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043951	A1	20040527	WO 2003-EP311855	20031024

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003282051	A1	20040603	AU 2003-282051	20031024
PRIORITY APPLN. INFO.:			EP 2002-360298	A 20021024
			EP 2002-360372	A 20021220
			EP 2002-360373	A 20021220
			US 2003-456954P	P 20030325
			EP 2003-360070	A 20030611
			EP 2003-360091	A 20030724
			WO 2003-EP11855	W 20031024

OTHER SOURCE(S): MARPAT 141:7108

GI



I



II

AB Title compds. I [wherein R1 = H, CF3, (un)substituted alkyl, cycloalkyl, heterocyclyl, etc.; R2 = (un)substituted alkyl, amino, COH, etc.; n = 0-6; R11 and R12 = independently H, alkyl, CO2H and derivs., OH and derivs., NH2 and derivs., etc.; their analogs, derivs., solvates or salts] were prepd. for modulating peroxisome proliferator activated receptors (PPARs), in particular as PPAR.gamma. agonists, and for treating and/or preventing various diseases and conditions mediated by said nuclear receptors, including metabolic or cell proliferative disorders (no data). For example, 1-phenyl-3-(thiophen-2-yl)-1H-pyrazole-4-carboxaldehyde (prepn. given) was reacted with 1-(4-methoxyphenyl)ethanone in isopropanol to give II in 67% yield. II inhibited adipocyte differentiation induced by rosiglitazone by about 68%, demonstrating its antagonistic activity towards human PPAR.gamma.. II induced adipocyte differentiation (25% of rosiglitazone efficacy), proving its human PPAR.gamma. partial agonistic activity. I are useful for treating diabetes, atherosclerosis, hyperglycemia, dyslipidemia, obesity, syndrome X, insulin resistance, hypertension, neuropathy, microvascular diseases (e.g.

retinopathy, nephropathy), macrovascular diseases (e.g. myocardial infarction, stroke, heart failure) in mammals.(no data).

102e/102a, possible interfering 10/517,214

L8 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:951003 CAPLUS Full-text
DOCUMENT NUMBER: 140:16723
TITLE: Preparation of 1,2-azole derivatives with hypoglycemic and hypolipidemic activity
INVENTOR(S): Maekawa, Tsuyoshi; Hara, Ryoma; Odaka, Hiroyuki; Kimura, Hiroyuki; Mizufune, Hideya; Fukatsu, Kohji
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan; Takeda Pharmaceutical Company Limited
SOURCE: PCT Int. Appl., 564 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003099793	A1	20031204	WO 2003-JP6389	20030522
WO 2003099793	A8	20041229		
WO 2003099793	A9	20050210		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2487315	A1	20031204	CA 2003-2487315	20030522
AU 2003241173	A1	20031212	AU 2003-241173	20030522
JP 2004277397	A	20041007	JP 2003-144984	20030522
EP 1513817	A1	20050316	EP 2003-730575	20030522
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006148858	A1	20060706	US 2005-517214	20050301

PRIORITY APPLN. INFO.:

JP 2002-151405	A	20020524
JP 2002-287161	A	20020930
JP 2003-16748	A	20030124
WO 2003-JP6389	W	20030522

OTHER SOURCE(S): MARPAT 140:16723
GI



I

AB 1,2-Azole derivs. A-B-Xa-Ya-Xb-Yb-C-Xc-Yc-C(:O)-R (I; e.g. II) wherein ring A optionally has 1-3 substituents; ring B is a 1,2-azole ring which may further have 1 to 3 substituents; Xa, Xb and Xc are the same or different and each is a bond, -O-, -S- and the like; Ya is a divalent aliph. hydrocarbon residue having 1-20 C atoms; Yb and Yc are the same or different and each is a bond or a divalent aliph. hydrocarbon residue having 1-20 C atoms; ring C is a monocyclic arom. ring which may further have 1 to 3 substituents; and R = -OR4 (R4 is H atom or (un)substituted hydrocarbon group) and the like, or a salt thereof or a prodrug thereof is useful as an agent for the prophylaxis or treatment of diabetes and the like. Hypoglycemic and hypolipidemic actions in mice are tabulated for about 50 examples of I; e.g. a 53 % rate of decrease in blood glucose level in the presence of 0.005 % [2-[3-[3-isopropyl-1-[5-(trifluoromethyl)-2-pyridinyl]-1H-pyrazol-4-yl]propoxy]-3- methylphenyl]acetic acid and a 77 % rate of decrease in blood triglyceride level in the presence of 0.005 % 2-methyl-2-[4-[3-methyl-1-[5- (trifluoromethyl)-2-pyridyl]-1H-pyrazol-4-ylmethoxy]phenoxy]propionic acid when the level (glucose or triglyceride) of the non-treated group is taken as 100 %. Plasma anti-arteriosclerosis index-enhancing action in mice is tabulated for 34 examples of I, e.g. 25 % for [3-methoxy-2-[3-[3-propyl-1- [5-(trifluoromethyl)-2-pyridyl]-1H-pyrazol-4-yl]propoxy]phenyl]acetic acid. PPAR.gamma.-RXR.alpha. and PPAR.delta.-RXR.alpha. heterodimer ligand activity is tabulated for 59 and 80 examples, resp., of I, e.g. EC50 = 3.8 nM for PPAR.gamma.-RXR.alpha. for [2-[3-[3-cyclohexyl-1-[5- (trifluoromethyl)-2-pyridinyl]-1H-pyrazol-4-yl]propoxy]-3- methylphenyl]acetic acid. Nearly 400 example prepns. of I and 351 example prepns. of intermediates are included. For example, [4-[3-[3-[4-(trifluoromethyl)phenyl]-5-isoxazolyl]propoxy]phenyl]acetic acid was obtained in 25 % yield from a mixt. of 3-[3-[4-(trifluoromethyl)phenyl]-5- isoxazolyl]-1-Pr methanesulfonate, NaI, Me 2-(4-hydroxyphenyl)acetate, K2CO3 and DMF; details of the prepn. of the mesylate are also given.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l7 ibib abs tot

L7 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1026833 CAPLUS Full-text

DOCUMENT NUMBER: 143:326090

TITLE: Preparation of arylmethoxyphenyl-alkylcarboxylic acids and related derivatives for use in treating metabolic disorders

INVENTOR(S): Akerman, Michelle; Houze, Jonathan; Lin, Daniel C. H.; Liu, Jiwen; Luo, Jian; Medina, Julio C.; Qiu, Wei;

Reagan, Jeffrey D.; Sharma, Rajiv; Shuttleworth, Stephen J.; Sun, Ying; Zhang, Jian; Zhu, Liusheng

PATENT ASSIGNEE(S): Amgen Inc., USA; et al.

SOURCE: PCT Int. Appl., 163 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005086661	A2	20050922	WO 2005-US5815		20050224
WO 2005086661	A3	20060504			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2005220728	A2	20050922	AU 2005-220728		20050224
AU 2005220728	A1	20050922			
CA 2558585	A1	20050922	CA 2005-2558585		20050224
EP 1737809	A2	20070103	EP 2005-723623		20050224
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU					
CN 1946666	A	20070411	CN 2005-80012709		20050224
US 2006004012	A1	20060105	US 2005-67377		20050225
MX 2006PA09793	A	20061030	MX 2006-PA9793		20060828
US 2007142384	A1	20070621	US 2006-591214		20060828
NO 2006004362	A	20061122	NO 2006-4362		20060926
PRIORITY APPLN. INFO.:			US 2004-548741P	P	20040227
			US 2004-601579P	P	20040812
			WO 2005-US5815	W	20050224

OTHER SOURCE(S): MARPAT 143:326090

GI



II

AB Title compds. Q-L1-P-L2-M-X-L3-A [Q = H, (hetero)aryl, alkyl, etc.; L1 = bond, alkylene, heteroalkylene, O, etc.; P = (hetero)arom., cycloalkylene, etc.; L2 = bond, alkylene, heteroalkylene, etc.; M = (hetero)arom., cycloalkylene,

arylalkylene, etc.; X = divalent alkyl, (un)substituted-N; O, SO0-2; L3 = bond, alkylene, heteroalkylene, etc.; A = COOH, tetrazolyl, SO3H, PO3H2, etc.; I] are prepd. For instance, (S)-3-[4-((4'- trifluoromethyl-1,1'-biphenyl-3-yl)methoxy)phenyl]hexan-4-ynoic acid (II) is prepd. in 5 steps from (S)-3-(4-hydroxyphenyl)hexan-4-ynoic acid Me ester (prepn. given), 4-(trifluoromethyl)phenylboronic acid and 3-bromobenzoic acid. II has an EC50 < 0.1 .mu.M for human G protein-coupled receptor GPR40. I are useful for the treatment of type II diabetes.

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:606448 CAPLUS Full-text
DOCUMENT NUMBER: 141:157111
TITLE: Preparation of pyrazoles and analogs as PPAR modulators for treatment of metabolic disorders, diabetes mellitus, atherosclerosis, and cardiovascular disorders
INVENTOR(S): Conner, Scott Eugene; Ma, Tianwei; Mantlo, Nathan Bryan; Mayhugh, Daniel Ray; Schkeryantz, Jeffrey Michael; Warshawsky, Alan M.; Zhu, Guoxin
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 214 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004063166	A1	20040729	WO 2003-US39119	20031231
WO 2004063166	A8	20050303		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003296404	A1	20040810	AU 2003-296404	20031231
EP 1585733	A1	20051019	EP 2003-815195	20031231
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, BG, CZ, EE, HU, SK				
US 2006241157	A1	20061026	US 2005-540341	20050621

PRIORITY APPLN. INFO.:
US 2003-438563P P 20030106
WO 2003-US39119 W 20031231

OTHER SOURCE(S): MARPAT 141:157111
GI



I



II

AB Title pyrazoles, imidazoles, and (is)oxazoles I [wherein R1 = H, (un)substituted alkyl, alkenyl, (hetero)aryl(alkyl), arylheteroalkyl, cycloalkylaryl(alkyl); R2 = absent, (hetero)alkyl; R8 = H, alkyl, alkylenyl, halo; R9 = H, (un)substituted alkyl, alkylenyl, halo, aryl(alkyl), heteroaryl, allyl, alkoxy, alkylthio, etc.; R10, R11 = independently H, OH, CN, NO2, halo, oxo, (un)substituted (halo)alkyl, alkoxy, cycloalkyl, (hetero)aryl(alkyl), cycloalkylaryl(alkyl), aryloxy, acyl, carboxy, amino, sulfamoyl, etc.; R32 = bond, H, halo, (halo)alkyl, alkyloxo; E = (un)substituted carboxy(methyl), tetrazolyl(methyl), nitriloalkyl, carboxamido(methyl), sulfonamido(methyl); U = (un)substituted aliph. linker wherein one C of the linker is optionally replaced with O, NH, or S; X = bond, O, S, SO2, NH; Y = bond, CH2, NH; Z1, Z2 = independently N, O, C, whit the proviso that at least one of Z1 and Z2 = N; Z3 = N, O, C; or stereoisomers, pharmaceutically acceptable salts, solvates, and hydrates thereof] were prepd. as peroxisome proliferator activated receptor (PPAR) modulators (no data). For example, chlorination of [3-methyl-1-(4-trifluoromethylphenyl)-1H-pyrazol-4-yl]methanol with MeSO2Cl and TEA in CH2Cl2, followed by coupling with (4-hydroxy-2- methylphenoxy)acetic acid Me ester using Cs2CO3 in acetonitrile and sapon. with NaOH in MeOH provided II. I and their pharmaceutical compns. are expected to be effective in treating and preventing metabolic disorders, diabetes mellitus, atherosclerosis, and cardiovascular disorders (no data).

=>

=>
Executing the logoff script...

=> LOG H

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	257.87	442.63

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-52.26	-52.26

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 06:43:06 ON 30 JUL 2007